

Supplemental Table S1. Search Terms and Number of Records.

PubMed

((("Diet, Vegetarian"[Mesh] OR "Diet, Vegan"[Mesh] OR plant-based OR plant-based diet OR vegetarian OR vegan) AND (("Diabetes Mellitus"[Mesh] OR "Diabetes Mellitus, Type 2"[Mesh] OR diabetes OR type 2 diabetes OR type II diabetes OR non-insulin dependent diabetes OR NIDDM) OR ("Cardiovascular Diseases"[Mesh] OR "Stroke"[Mesh] OR "Coronary Disease"[Mesh] OR "Heart Diseases"[Mesh] OR "Coronary Artery Disease"[Mesh] OR "Myocardial Infarction"[Mesh] OR "Angina Pectoris"[Mesh] OR "Heart Failure"[Mesh] OR "Myocardial Ischemia"[Mesh] OR "Ischemic Stroke"[Mesh] OR "Hemorrhagic Stroke"[Mesh] OR "Cerebrovascular Disorders"[Mesh] OR cardiovascular diseases OR stroke OR cardiovascular OR coronary heart disease OR heart disease OR coronary artery disease OR myocardial infarction OR angina pectoris OR heart failure OR CHD OR CVD OR ischemic heart disease OR ischaemic heart disease OR ischaemic stroke OR ischemic stroke OR haemorrhagic stroke OR hemorrhagic stroke OR cerebrovascular disease) OR ("Neoplasms"[Mesh] OR "Carcinoma"[Mesh] OR cancer OR total cancer OR carcinoma OR tumor OR neoplasm) OR ("Mortality"[Mesh] OR "Survival"[Mesh] OR "Death"[Mesh] OR mortality OR all-cause mortality OR total mortality OR survival OR death))) AND (Human)

Records found: 4313

EMBASE

('vegetarian diet'/exp OR 'vegan diet'/exp OR 'plant diet':ti,ab,kw OR 'plant-based diet':ti,ab,kw OR 'vegetarian diet':ti,ab,kw OR 'vegan diet':ti,ab,kw) AND ('diabetes mellitus'/exp OR 'non insulin dependent diabetes mellitus'/exp OR 'diabetes mellitus':ti,ab,kw OR 'non insulin dependent diabetes mellitus':ti,ab,kw OR 'type 2 diabetes':ti,ab,kw OR 'type ii diabetes':ti,ab,kw OR 'cardiovascular disease'/exp OR 'ischemic heart disease'/exp OR 'heart disease'/exp OR 'coronary artery disease'/exp OR 'heart infarction'/exp OR 'angina pectoris'/exp OR 'heart failure'/exp OR 'ischemic stroke'/exp OR 'brain hemorrhage'/exp OR 'cerebrovascular disease'/exp OR 'cardiovascular diseases':ti,ab,kw OR 'stroke':ti,ab,kw OR 'cardiovascular':ti,ab,kw OR 'coronary heart disease':ti,ab,kw OR 'heart disease':ti,ab,kw OR

'coronary artery disease':ti,ab,kw OR 'myocardial infarction':ti,ab,kw OR 'angina pectoris':ti,ab,kw OR 'heart failure':ti,ab,kw OR 'ischemic heart disease':ti,ab,kw OR 'ischaemic heart disease':ti,ab,kw OR 'ischaemic stroke':ti,ab,kw OR 'ischemic stroke':ti,ab,kw OR 'haemorrhagic stroke':ti,ab,kw OR 'hemorrhagic stroke':ti,ab,kw OR 'cerebrovascular disease':ti,ab,kw OR 'malignant neoplasm'/exp OR 'carcinoma'/exp OR 'neoplasm'/exp OR 'cancer':ti,ab,kw OR 'total cancer':ti,ab,kw OR 'carcinoma':ti,ab,kw OR 'tumor':ti,ab,kw OR 'neoplasm':ti,ab,kw OR 'mortality'/exp OR 'all cause mortality'/exp OR 'survival'/exp OR 'death'/exp OR 'mortality':ti,ab,kw OR 'all cause mortality':ti,ab,kw OR 'total mortality':ti,ab,kw OR 'survival':ti,ab,kw OR 'death':ti,ab,kw) AND 'human'/exp AND [embase]/lim

Records found: 2451

Web of Science

TS=(((plant-based OR plant-based diet OR vegetarian OR vegan) AND ((diabetes OR type 2 diabetes OR type II diabetes OR non-insulin dependent diabetes OR NIDDM) OR (cardiovascular diseases OR stroke OR cardiovascular OR coronary heart disease OR heart disease OR coronary artery disease OR myocardial infarction OR angina pectoris OR heart failure OR CHD OR CVD OR ischemic heart disease OR ischaemic heart disease OR ischaemic stroke OR ischamic stroke OR haemorrhagic stroke OR hemorrhagic stroke OR cerebrovascular disease) OR (cancer OR total cancer OR carcinoma OR tumor OR neoplasm) OR (mortality OR all-cause mortality OR total mortality OR survival OR death))))

Records found: 5572

Supplemental Table S2. Inclusion/Exclusion Criteria for Literature Search.

Inclusion criteria

- Prospective cohort studies, prospective case-cohort studies, or nested prospective case-control studies
- Clear definition of dietary exposure (used a priori-defined dietary patterns with emphasis on the plant-based foods and de-emphasis or avoidance on the animal foods) assessed using validated dietary assessment methods
- Multivariate adjusted effect estimates (odds ratio, relative risk, rate ratio, or hazard ratio)
- Human studies

Exclusion criteria

- Retrospective case-control studies, cross-sectional and ecological studies, literature reviews, commentaries, editorials, letters, case reports, and meeting abstracts
 - Primary outcome involves conditions that are not type 2 diabetes (such as type 1 diabetes, children with type 2 diabetes, gestational diabetes, prediabetes, or impaired glucose tolerance), cardiovascular disease, cancer, or mortality
 - Unclear definitions of dietary exposure or measurements
 - Used a posteriori approach (e.g., principal component analysis, factor analysis) to derive dietary patterns
 - Crude effect estimates only
 - Non-human animal studies
 - No full text
-

Supplemental Table S3. Baseline Characteristics of Published Studies Examining Plant-Based Dietary Patterns and Incident Type 2 Diabetes, Cardiovascular Disease, Cancer, and Mortality.

| Source | Study name | Region | Disease outcome | Case/ total number | Mean age (year) | Mean BMI (kg/m ²) | Men (%) | Follow up (year) | Diet assessment | Exposure | Disease ascertainment | Model adjustment |
|-----------------------------|-------------------------------|-----------------------------------|-----------------|-----------------------|-----------------------|-------------------------------------|------------|------------------------|--------------------|--|---|--|
| Vang et al (1), 2008 | AHS and AMS | United States | T2D | 543/ 8,401 | 64.6 | 24.5 | 61.1 | Median 17.0 | FFQ | Vegetarian, occasional meat intake vs. nonvegetarian | Self-reported | Age, sex, and BMI |
| Tonstad et al (2), 2013 | AHS-2 | United States and Canada | T2D | 616/ 41,387 | 58.0 | 26.7 | 36.7 | Median 2.0 | FFQ | Vegan, lacto- ovo-vegetarian, pesco-ovo- vegetarian, semi- vegetarian vs. nonvegetarian | Self-reported with validated questionnaire | Age, BMI, race/ethnicity, sex, educational level, income, television watching, sleep, alcohol intake, physical activity, and smoking |
| Satija et al (3), 2016 | NHS | United States | T2D | 7,711/ 69,949 | 50.0 | 25.0 | 0 | Maximu m 28.0 | FFQ | PDI, hPDI, uPDI, comparing extreme deciles | Self-reported with confirmation by a validated supplementary questionnaire, diagnosis criteria per the National Diabetes Data Group | Age, smoking, physical activity, alcohol intake, multivitamin use, family history of diabetes, total energy intake, hypertension, hypercholesterolemia, menopausal status or hormone replacement use, and BMI |
| Satija et al (3), 2016 | NHSII | United States | T2D | 5,200/ 90,239 | 36.0 | 25.0 | 0 | Maximu m 20.0 | FFQ | PDI, hPDI, uPDI, comparing extreme deciles | Self-reported with confirmation by a validated supplementary questionnaire, diagnosis criteria per the National Diabetes Data Group | Age, smoking, physical activity, alcohol intake, multivitamin use, family history of diabetes, total energy intake, hypertension, hypercholesterolemia, menopausal status or hormone replacement use, oral contraceptive, and BMI |
| Satija et al (3), 2016 | HPFS | United States | T2D | 3,251/ 40,539 | 53.0 | 25.2 | 100 | Maximu m 24.0 | FFQ | PDI, hPDI, uPDI, comparing extreme deciles | Self-reported with confirmation by a validated supplementary questionnaire, diagnosis criteria per the National Diabetes Data Group | Age, smoking, physical activity, alcohol intake, multivitamin use, family history of diabetes, total energy intake, hypertension, hypercholesterolemia, and BMI |
| Chen et al (4), 2018 (a) | Rotterdam Study I, II, III | The Netherla nds | T2D | 642/ 6,770 | 62.0 | 26.6 | 41.3 | Median 7.3 | FFQ | PDI, comparing per 10 units higher score, converted to | Diagnosis information was collected from general practitioners' records, pharmacy | Age, sex, energy intake, Rotterdam Study Sub-cohort, education, smoking, family history of diabetes, physical |

| Source | Study name | Region | Disease outcome | Case/ total number | Mean age (year) | Mean BMI (kg/m ²) | Men (%) | Follow up (year) | Diet assessment | Exposure | Disease ascertainment | Model adjustment |
|--------------------------|--|----------------|-----------------|-----------------------|-----------------------|-------------------------------------|------------|------------------------|--------------------|---|--|--|
| | | | | | | | | | | comparing extreme quintiles | databases, and follow-up examinations. Confirmation was judged by two physicians, discrepancies were settled by consulting an endocrinologist | activity, food supplement use, and BMI |
| Chen et al (5), 2018 (b) | Singapore Chinese Health Study | Singapore | T2D | 5,207/ 45,411 | 55.2 | 23.0 | 42.7 | Median 11.2 | FFQ | PDI, hPDI, comparing extreme quintiles | Self-reported and validated through linkage with nationwide hospital discharge database, supplementary questionnaire, or analysis of blood samples | Age, sex, dialect group, year of interview, energy intake, physical activity, BMI, education, smoking, hypertension, and alcohol use |
| Chiu et al (6), 2018 | The Tzu Chi Health Study | Taiwan | T2D | 183/ 2,918 | 53.2 | 23.3 | 81.2 | Median 5.0 | FFQ | Vegetarian diet, reverted vegetarian, converted vegetarian vs nonvegetarian (Baseline and change in diet) | Self-reported on questionnaires or HbA1c \geq 6.5%; in cases with uncertain diagnosis, medical record review was performed | Age, sex, education, physical activity, family history of diabetes, follow-up methods (Health examination or questionnaire only), use of lipid medication, and BMI |
| Papier et al (7), 2019 | EPIC-Oxford | United Kingdom | T2D | 1,224/ 65,411 | 44.5 | 23.5 | 76.1 | Mean 17.6 | FFQ | Vegetarians and vegans, fish eaters, low meat eaters vs. regular meat eaters | Health record linkage to National Health Service Central Registers | Age, education, Townsend deprivation index, ethnicity, smoking, alcohol intake, physical activity, and BMI |
| Choi et al (8), 2020 | The Coronary Artery Risk Development in Young Adults | United States | T2D | 206/ 2,534 | 25.2 | 24.0 | 42.6 | Mean 9.3 | FFQ | 20-year change in APDQS comparing extreme quintiles (Change in adherence of plant-based diet) | Fasting glucose concentration \geq 126 mg/dL, 2-h post challenge glucose concentration \geq 200 mg/dL (Y10, Y20, and Y25), HbA1c \geq 6.5% (Y20 and Y25), and/or use of self-reported antidiabetic medications (brought medication bottle) | Age (Y20), sex, race, total energy intake (Y20), parental history of diabetes, physical activity level (Y20), smoking status (Y20), highest grade of education achieved during follow-up, and BMI (Y20). |
| Chen et al (9), 2021 | NHS | United States | T2D | 5,993/ 76,530 | 58.1 | 25.4 | 0 | Maximum 26.0 | FFQ | Change in PDI, hPDI, uPDI, comparing large | Self-reported with confirmation by a | Age and initial corresponding plant-based diet score, ethnicity, family history of diabetes, initial |

| Source | Study name | Region | Disease outcome | Case/ total number | Mean age (year) | Mean BMI (kg/m ²) | Men (%) | Follow up (year) | Diet assessment | Exposure | Disease ascertainment | Model adjustment |
|-----------------------------|--|------------------|-----------------|-----------------------|-----------------------|-------------------------------------|------------|------------------------|--------------------|---|--|---|
| | | | | | | | | | | increase (>10%) vs. no change (Change in adherence of plant-based diet) | validated supplementary questionnaire, diagnosis criteria per the National Diabetes Data Group | and change in total energy, alcohol intake, margarine intake and physical activity, change in smoking status, initial BMI, history of hypertension, history of hypercholesterolemia, menopausal status, and postmenopausal hormone use |
| Chen et al (9), 2021 | NHSII | United States | T2D | 4,190/ 81,569 | 41.1 | 24.6 | 0 | Maximum 26.0 | FFQ | Change in PDI, hPDI, uPDI, comparing large increase (>10%) vs. no change (Change in adherence of plant-based diet) | Self-reported with confirmation by a validated supplementary questionnaire, diagnosis criteria per the National Diabetes Data Group | Age and initial corresponding plant-based diet score, ethnicity, family history of diabetes, initial and change in total energy, alcohol intake, margarine intake and physical activity, change in smoking status, initial BMI, history of hypertension, history of hypercholesterolemia, menopausal status, postmenopausal hormone use, and oral contraceptive use |
| Chen et al (9), 2021 | HPFS | United States | T2D | 2,444/ 34,468 | 57.5 | 25.4 | 100 | Maximum 30.0 | FFQ | Change in PDI, hPDI, uPDI, comparing large increase (>10%) vs. no change (Change in adherence of plant-based diet) | Self-reported with confirmation by a validated supplementary questionnaire, diagnosis criteria per the National Diabetes Data Group | Age and initial corresponding plant-based diet score, ethnicity, family history of diabetes, initial and change in total energy, alcohol intake, margarine intake and physical activity, change in smoking status, initial BMI, history of hypertension, history of hypercholesterolemia |
| Flores et al (10), 2021 | Boston Puerto Rican Health Study | United States | T2D | 134/646 | 55.5 | 29.7 | 28 | 4.2 | FFQ | PDI, hPDI, uPDI, comparing extreme tertiles | Phlebotomist took participants' fasting morning blood draw at their home. Diabetes status was defined as having fasting plasma glucose \geq 126 mg/dL (7.0 mmol/L), glycated hemoglobin \geq 6.5% (48 mmol/mol), or use of hypoglycemic agents. | Age, sex, education, marital status, income to poverty ratio, total energy, smoking status, alcohol frequency, physical activity score, psychological acculturation score, depressive symptomatology score, BMI. |
| Laouali et al (11), 2021 | The E3N Prospective Cohort Study | France | T2D | 3,292/ 70,991 | 52.9 | 22.9 | 0 | ~20 | FFQ | PDI, hPDI, uPDI, comparing extreme quintiles | Before 2004, T2D cases were identified through self-report and followed up with diabetes-specific questionnaire for | Age, family history of diabetes, educational level, hypercholesterolemia, hypertension, smoking status, physical activity, and energy intake. |

| Source | Study name | Region | Disease outcome | Case/ total number | Mean age (year) | Mean BMI (kg/m ²) | Men (%) | Follow up (year) | Diet assessment | Exposure | Disease ascertainment | Model adjustment |
|--------------------------------|---|----------------|-----------------|-----------------------|-----------------------|-------------------------------------|------------|------------------------|------------------------|---|--|---|
| | | | | | | | | | | | validation. After 2004, cases were identified through the drug reimbursement insurance database. | |
| Yang et al (12), 2021 | The Henan Rural Cohort Study | Mainland China | T2D | NA/ 37,985 | 55.7 | 24.8 | 39.3 | Maximum 7.0 | FFQ | PDI comparing extreme quartiles | Fasting glucose concentration ≥ 7.0 mmol/L (126 mg/dL) or self-reported T2D diagnosis and/or the use of insulin or blood glucose-lowering drugs in the past 2 weeks | Age, gender, education level, marital status, per capita monthly income, tobacco smoking, alcohol drinking, total energy intake, physical activity, hypertension, family history of diabetes, and BMI |
| Bhupathiraju et al (13), 2022 | Mediators of Atherosclerosis in South Asians Living in America (MASALA) study | United States | T2D | 45/735 | 55.3 | 26.0 | 53.0 | Mean 5 | FFQ | PDI, hPDI, uPDI, per 5 units increment | Defined by the use of a glucose-lowering medication, fasting plasma glucose ≥ 7.0 mmol/L, and/or glucose ≥ 11.1 mmol/L at 2 hours after the challenge | Age, sex, study site, education, smoking status, alcohol consumption, family history of diabetes, years lived in the United States, physical activity, total energy, diabetes medication use, cholesterol-lowering medication use, hypertension medication use, sum of cultural traditional measures, and BMI |
| Chen et al (14), 2022 (a) | China Nutrition and Health Survey | China | T2D | 720/8,211 | 46.1 | 22.9 | 48.3 | Median 10.2 | 24-hour dietary recall | PDI, hPDI, comparing extreme quintiles | In the 2009 survey, T2D was defined as meeting at least one of the following criteria: (1) fasting blood glucose concentration of ≥ 7.0 mmol/L (126 mg/dL), (2) HbA1c $\geq 6.5\%$, or (3) self-reported diagnosis of T2D or on hypoglycemic medication; In 2015, T2D was defined based on self-reported diabetes or taking hypoglycemic medication. | Age, sex, total energy intake, education, physical activity, smoking, alcohol consumption, baseline SBP & DBP, and BMI |
| Kim and Giovannucci (15), 2022 | Korean Genome and Epidemiology Study (KoGES) | Korean | T2D | 977/7,393 | 51.7 | 24.6 | 46.4 | Maximum 14 | FFQ | PDI, hPDI, uPDI, per 10-point increment | Defined by elevated plasma glucose (≥ 126 mg/dL), self-report of a doctor's diagnosis of | Age, sex, residential area, education, physical activity, smoking, alcohol consumption, baseline BMI, total energy intake, |

| Source | Study name | Region | Disease outcome | Case/ total number | Mean age (year) | Mean BMI (kg/m ²) | Men (%) | Follow up (year) | Diet assessment | Exposure | Disease ascertainment | Model adjustment |
|-------------------------------|---|------------------|-----------------|-----------------------|-----------------------|-------------------------------------|------------|------------------------|--------------------|--|---|--|
| Glenn et al (16), 2023 | WHI | United States | T2D | 13,943/145,299 | 63 | 27.8 | 0 | Median 16 | FFQ | Portfolio Diet comparing extreme quintiles. | T2D, or use of oral hypoglycemic drug. T2D were defined as a self-report of physician-diagnosed diabetes treated with oral medication or insulin, determined at each annual contact. | family history of diabetes, and history of hypertension Age, region, smoking, study arm, self-identified race and ethnicity, education, marital status, hysterectomy history, physical activity, alcohol intake, energy intake, hypertension status, family history of diabetes, HT use, cholesterol-lowering medication use, BMI. |
| Zhang et al (17), 2023 (a) | Malmö Diet and Cancer (MDC) study | Sweden | T2D | 4,197/24,494 | 58.1 | 25.6 | 38.5 | Median 24.3 | FFQ | EAT-Lancet diet, comparing extreme levels (≥23 vs. ≤13) | Diabetes cases were retrieved by linking the Swedish personal identification number with eight national and local registers as well as re-examination screenings of the study participants. | Age, sex, dietary assessment version, season, total energy intake, leisure-time physical activity, alcohol consumption, smoking status, educational level, family history of diabetes, lipid-lowering medication, hypertension at baseline, history of cardiovascular disease and cancer, BMI. |
| Satija et al (18), 2017 | NHS | United States | CVD (CHD) | 3,233/ 73,710 | 50.0 | 25.0 | 0 | Maximu m 28.0 | FFQ | PDI, hPDI, uPDI, comparing extreme deciles | Self-reported, confirmed by medical records | Age, smoking status, physical activity, alcohol intake, multivitamin use, aspirin use, family history of CHD, margarine intake, energy intake, baseline hypertension, hypercholesterolemia, and diabetes, updated BMI, and postmenopausal hormone use. |
| Satija et al (18), 2017 | NHSII | United States | CVD (CHD) | 667/ 92,329 | 36.5 | 25.0 | 0 | Maximu m 22.0 | FFQ | PDI, hPDI, uPDI, comparing extreme deciles | Self-reported, confirmed by medical records | Age, smoking status, physical activity, alcohol intake, multivitamin use, aspirin use, family history of CHD, margarine intake, energy intake, baseline hypertension, hypercholesterolemia, and diabetes, updated BMI, postmenopausal hormone use, and oral contraceptive use. |
| Satija et al (18), 2017 | HPFS | United States | CVD (CHD) | 4,731/ 43,259 | 53.5 | 25.5 | 100 | Maximu m 26.0 | FFQ | PDI, hPDI, uPDI, comparing extreme deciles | Self-reported, confirmed by medical records | Age, smoking status, physical activity, alcohol intake, multivitamin use, aspirin use, family history of CHD, margarine intake, energy intake, baseline hypertension, |

| Source | Study name | Region | Disease outcome | Case/ total number | Mean age (year) | Mean BMI (kg/m ²) | Men (%) | Follow up (year) | Diet assessment | Exposure | Disease ascertainment | Model adjustment |
|--------------------------|------------------------------------|-------------------|---|--|-----------------------|-------------------------------------|------------|------------------------|--------------------|---|--|--|
| Kim et al (19), 2019 | ARIC | United States | CVD (Total) | 4,381/ 12,168 | 53.8 | Obesity (20.7%) | 44.1 | Median 25 | FFQ | PDI, hPDI, uPDI, provegetarian diet index comparing extreme quintiles | Ascertained through annual telephone calls with participants or proxies, active surveillance of local hospital discharge records and state death records, and linkage to the National Death Index | hypercholesterolemia, and diabetes, and updated BMI. |
| Tong et al (20), 2019 | EPIC-Oxford | United Kingdom | CVD (IHD) CVD (Stroke) | 2,820/ 48,188 1,072/ 48,188 | 44.7 | 23.6 | 22.3 | 18.1 | FFQ | Vegetarians, fish eaters vs. meat eaters | Record linkage to United Kingdom's health service | Age, sex (stratified), method of recruitment (stratified), region (stratified), year of recruitment, education, Townsend deprivation index, smoking, alcohol consumption, physical activity, dietary supplement use, and oral contraceptive and hormone replacement therapy use in women |
| Chiu et al (21), 2020 | The Tzu Chi Health Study | Taiwan | CVD (stroke) | 54/ 5,050 | 52.3 | 23.6 | 35.9 | Maximum 7.0 | FFQ | Vegetarian vs. nonvegetarian | Record linkage to the National Health Insurance Research Database | Sex, smoking, alcohol drinking, betel nut, leisure time physical activities, education, hypertension, diabetes mellitus, dyslipidemia, ischemic heart disease, and BMI |
| Chiu et al (21), 2020 | The Tzu Chi Vegetarian Study | Taiwan | CVD (stroke) | 121/ 8,302 | 49.5 | NA | 34.1 | Maximum 9.0 | FFQ | Vegetarian vs. nonvegetarian | Record linkage to the National Health Insurance Research Database | Sex, smoking, alcohol drinking, betel nut, leisure time physical activities, education, hypertension, diabetes mellitus, dyslipidemia, ischemic heart disease, and BMI |
| Shan et al (22), 2020 | NHS | United States | CVD (Total) CVD (CHD) CVD (Stroke) | 10,562/ 74,930 18,092 (3 cohorts) 5,687 (3 cohorts) | 50.2 | 24.8 | 0 | Maximum 32.0 | FFQ | hPDI comparing extreme quintiles for total CVD; hPDI per 25 percentile (18 points) increment for CHD and stroke, and converted to comparing extreme quintiles | Self-reported, confirmed by medical records | Age, race/ethnicity, BMI, physical activity, smoking status, alcohol intake, menopausal status, marital status, living alone or with others, family history of myocardial infarction, total energy intake, multivitamin use, and aspirin use |
| Shan et al (22), 2020 | NHSII | United States | CVD (Total) CVD (CHD) | 2,029/ 90,864 18,092 (3 cohorts) | 36.1 | 24.5 | 0 | Maximum 26.0 | FFQ | hPDI comparing extreme quintiles | Self-reported, confirmed by medical records | Age, race/ethnicity, BMI, physical activity, smoking status, alcohol intake, menopausal status, oral contraceptive use, marital status, |

| Source | Study name | Region | Disease outcome | Case/ total number | Mean age (year) | Mean BMI (kg/m ²) | Men (%) | Follow up (year) | Diet assessment | Exposure | Disease ascertainment | Model adjustment |
|------------------------|------------|---------------|---|---|-----------------------|-------------------------------------|------------|------------------------|--------------------|---|--|---|
| | | | CVD (Stroke) | 5,687 (3 cohorts) | | | | | | | | living alone or with others, family history of myocardial infarction, total energy intake, multivitamin use, and aspirin use |
| Shan et al (22), 2020 | HPFS | United States | CVD (Total) CVD (CHD) CVD (Stroke) | 10,775/ 43,339 18,092 (3 cohorts) 5,687 (3 cohorts) | 53.2 | 25.4 | 100 | Maximum 26.0 | FFQ | hPDI comparing extreme quintiles | Self-reported, confirmed by medical records | Age, BMI, physical activity, smoking status, alcohol intake, marital status, living alone or with others, family history of myocardial infarction, total energy intake, multivitamin use, and aspirin use |
| Baden et al (23), 2021 | NHS | United States | CVD (Stroke) | 3,604/ 73,890 | 50.5 | 24.9 | 0 | Maximum 32.0 | FFQ | PDI, hPDI, uPDI, comparing extreme quintiles | Self-reported with confirmation with additional detail by letter/interview and medical records | Race, physical activity, alcohol consumption, margarine, total energy intake, smoking, aspirin use, multivitamin use, BMI, postmenopausal hormone therapy, hypertension, hypercholesterolemia, diabetes, antihypertensive use, and anticholesterol medication use |
| Baden et al (23), 2021 | NHSII | United States | CVD (Stroke) | 740/ 92,352 | 36.5 | 24.6 | 0 | Maximum 26.0 | FFQ | PDI, hPDI, uPDI, comparing extreme quintiles | Self-reported with confirmation with additional detail by letter/interview and medical records | Race, physical activity, alcohol consumption, margarine, total energy intake, smoking, aspirin use, multivitamin use, BMI, postmenopausal hormone therapy, oral contraceptives, hypertension, hypercholesterolemia, diabetes, antihypertensive use, and anticholesterol medication use |
| Baden et al (23), 2021 | HPFS | United States | CVD (Stroke) | 1,897/ 43,266 | 53.5 | 25.5 | 100 | Maximum 26.0 | FFQ | PDI, hPDI, uPDI, comparing extreme quintiles | Self-reported with confirmation with additional detail by letter/interview and medical records | Race, physical activity, alcohol consumption, margarine, total energy intake, smoking, aspirin use, multivitamin use, BMI, hypertension, hypercholesterolemia, diabetes, antihypertensive use, and anticholesterol medication use |
| Glenn et al (24), 2021 | WHI | United States | CVD (Total) CVD (CHD) CVD (Heart failure) CVD (Stroke) | 13,365/ 123,330 5,640/ 123,330 1,907/ 123,330 4,440/ 123,330 | 62.7 | 27.8 | 0 | Mean 15.3 | FFQ | Plant-based dietary pattern comparing extreme quartiles | Self-reported with confirmation with medical records | Age, region, smoking, and study arm, race/ethnicity, education, marital status, hysterectomy history, BMI, physical activity, alcohol intake, energy intake, cancer status, hypertension status, diabetes mellitus status, sodium intake, family history of CVD, family history of diabetes mellitus, |

| Source | Study name | Region | Disease outcome | Case/ total number | Mean age (year) | Mean BMI (kg/m ²) | Men (%) | Follow up (year) | Diet assessment | Exposure | Disease ascertainment | Model adjustment |
|----------------------------------|--|----------------|---|--|-----------------------|-------------------------------------|------------|------------------------|------------------------|--|---|---|
| Petermann-Rocha et al (25), 2021 | UK Biobank | United Kingdom | CVD (Total) CVD (Heart failure) CVD (IHD) CVD (MI) CVD (Stroke) | 106,690/ 422,791 7,685/ 422,791 24,794/ 422,791 6,770/ 422,791 5,946/ 422,791 | 56.4 | 27.3 | 44.6 | Median 8.5 | 24-hour dietary recall | Vegetarians, fish eaters, fish, and poultry eaters vs. meat-eaters | Record linkage to registries | hormone therapy use, and cholesterol-lowering medication use Age, sex, deprivation, ethnicity, comorbidities, smoking, alcohol intake, total sedentary time, physical activity, and BMI |
| Chen et al (26), 2022 (b) | Hispanic Community Health Study/Study of Latinos (HCHS/SOL) | United States | CVD | 232/10,293 | 40.9 | 29.3 | 41.5 | Mean 6 | 24-hour dietary recall | hPDI, comparing extreme tertiles | Self-reported | Age, sex, field center, Hispanic/Latino background, generational status, education, smoking, alcohol consumption, total energy intake, physical activity, BMI, and use of antidiabetic drugs, antihypertensive drugs, or lipid-lowering drugs |
| Choi et al (27), 2022 | The Coronary Artery Risk Development in Young Adults (CARDIA) cohort | United States | CVD (CHD) CVD (Stroke) | 116/4,701 80/4,701 | 24.9 | 24.4 | 44.8 | Median 32 years | FFQ | A Priori Diet Quality Score (APDQS) comparing extreme quintiles | Annual follow-ups and medical record reviews | Age, sex, race, total energy intake, maximal educational attainment, parental history of CVD, pack-years of smoking, physical activity, use of lipid-lowering medications, and BMI. |
| Ibsen et al (28), 2022 | Danish Diet, Cancer and Health cohort | Denmark | CVD (Stroke) | 2,253/55,016 | 56 | 25.5 | 48 | Median 15 | FFQ | EAT-Lancet diet, comparing extreme levels (11-14 vs. 0-7) | Incident cases of stroke were identified by linkage of each participant's civil registration number to the Danish National Patient Registry | Age, sex, date of inclusion and age at inclusion, education, smoking status, physical activity, alcohol intake, and hormone replacement therapy. |
| Kouvari et al (29), 2022 | ATTICA | Greece | CVD (Total) | 317/2,020 | 40 | 25.7 | 55 | Median 8.4 | FFQ | PDI, hPDI, uPDI, comparing extreme tertiles | A CVD event was defined according to the ICD-10 criteria, as the development of acute myocardial infarction, or unstable angina, or other identified forms of ischemia (410–414.9, 427.2, 427.6), or heart failure of different types and chronic | Age, sex, educational level, smoking habits, physical activity, body mass index, family history of CVD, personal history of diabetes mellitus, hypercholesterolemia and hypertension, alcohol consumption, energy intake. |

| Source | Study name | Region | Disease outcome | Case/ total number | Mean age (year) | Mean BMI (kg/m ²) | Men (%) | Follow up (year) | Diet assessment | Exposure | Disease ascertainment | Model adjustment |
|-------------------------------|---|------------------|--|---|-----------------------------|-------------------------------------|------------|--------------------------|---------------------------|--|--|--|
| Lazarova et al (30), 2022 | Canadian Community Health Survey (CCHS) - Nutrition | Canada | CVD | 748/6,771 | Rranges between 45-80 | NA | NA | Maximu m 13 | 24-hour dietary recall | Revised PDI, hPDI, uPDI, comparing extreme quintiles | arrhythmias (400.0– 404.9, 427.0–427.5, 427.9-) or stroke (430– 438). Record linkage to Canadian Vital Statistics-Death Database and Discharge Abstract Database, classified according to ICD-10 | Age, day of the week on which 24- h dietary recall was collected, education, smoking, misreporting, physical activity, marital status, immigrant, and alcohol consumption |
| Zhang et al (31), 2023 (b) | Malmö Diet and Cancer (MDC) study | Sweden | CVD (CHD) | 3,031/32,877 | 57.9 | 25.6 | 37.5 | Median 24.9 | FFQ | EAT-Lancet diet, comparing extreme levels (≥23 vs. ≤13) | Coronary events (including fatal and nonfatal myocardial infarction or death due to ischemic heart disease) were extracted from the Hospital Discharge Registers and cause of death register, using the ICD-9, of 410–414. | Age, sex, dietary assessment version, season, total energy intake, leisure-time physical activity, alcohol consumption, smoking status, educational level, BMI. |
| Thompson et al (32), 2023 | UK Biobank | UK | Mortality (Total) Mortality (CVD) Mortality (Cancer) CVD (Total) CVD (MI) CVD (Ischemic stroke) CVD (Hemorrhagic stroke) Cancer (Total) Cancer (Prostate) Cancer (Colorectal) Cancer (Breast) | 5627/126,217 698/126,217 3275/126,217 6,890/126,217 3,253/126,217 1,151/126,217 469/126,217 8,939/126,217 2,137/126,217 959/126,217 1,083/126,217 | 56.1 | 26.7 | 44.1 | 10.6- 12.2 | FFQ | hPDI, uPDI, comparing extreme quartiles | Data on mortality were available from the National Health Service death registries. CVD end points data were available from the Hospital Episode Statistics for England, Scottish Morbidity Records, and the Patient Episode Database for Wales. Cancer diagnosis data were provided through record linkage to National Cancer Registries in England, Wales, and Scotland. | Age, sex, body mass index, race and ethnicity, physical activity level, smoking status, alcohol intake, education level, energy intake, polypharmacy index, multimorbidity index, and aspirin use, stratified by region, prevalent CVD and prevalent cancer |
| Weston et al (33), 2022 | Jackson Heart Study (JHS) | United States | CVD Mortality (Total) | 293/3,635 597/3,635 | 54.5 | 31.8 | 36 | Median 13-15 years | FFQ | PDI, hPDI, uPDI, comparing extreme tertiles | Phone interview, hospitalizations surveillance, and death certificates reviewed | Age, sex, total energy intake, educational attainment, smoking status, alcohol intake, margarine intake, physical activity, BMI, total cholesterol, hypertension, diabetes, |

| Source | Study name | Region | Disease outcome | Case/ total number | Mean age (year) | Mean BMI (kg/m ²) | Men (%) | Follow up (year) | Diet assessment | Exposure | Disease ascertainment by medical professionals | Model adjustment estimated glomerular filtration rate, hormone replacement therapy medication use, and statin use. |
|--------------------------------|--|-----------------|--|--|-----------------------|-------------------------------------|------------|------------------------|--------------------|---|--|---|
| Berkel and de Waard (34), 1983 | Seventh-Day Adventists in the Netherlands | The Netherlands | Mortality (Total) Mortality (Cancer) Mortality (CVD) | 482/ 3,217 227/ 3,217 113/ 3,217 | NA | NA | 33.0 | 10 | NA | Vegetarian vs. general Dutch population | Church records and linkage to the Central Bureau of Statistics | Age |
| Ogata et al (35), 1984 | Japanese male Zen priests study | Japan | Mortality (Total) | 1,396/ 4,352 | ≥20 | NA | 100 | Maximum 23.0 | NA | Vegetarians vs. general Japanese male | Asking offices of municipalities whether they are still alive | Age, sex, calendar year (5-year intervals) specific person-years at risk |
| Thorogood et al (36), 1994 | Non-meat eaters and meat eaters in the United Kingdom | United Kingdom | Mortality (Total) Mortality (Cancer) Mortality (IHD) | 404/ 11,130 164/ 11,130 94/ 11,130 | 39.0 | BMI ≥24.1 20% | 39.0 | 12.0 | FFQ | Non-meat eaters vs. meat eaters | Record linkage with National Health Service central register, death certificates for those who subsequently died were obtained | Social class, smoking, and BMI |
| Key et al (37), 1996 | Vegetarian and health-conscious people in the United Kingdom | United Kingdom | Mortality (Total) | 1,343/ 10,771 | 45.8 | NA | 40.3 | Mean 16.8 | FFQ | Vegetarians vs. general United Kingdom population | Obtaining death certificates during follow-up | Age |
| Key et al (38), 1999 | AMS | United States | Mortality (Total) Mortality (IHD) Mortality (Cancer) | 1,635/ 24,538 598/ 24,538 118/ 24,538 | 51.0 | 24.9 | 36.7 | Mean 5.6 | FFQ | Vegetarian vs. nonvegetarian | Record linkage and personal contact | Age, sex, and smoking status |
| Key et al (38), 1999 | AHS | United States | Mortality (Total) Mortality (IHD) Mortality (Cancer) | 3,564/ 28,952 921/ 28,952 298/ 28,952 | 52.2 | 24.6 | 42.2 | Mean 11.1 | FFQ | Vegetarian vs. nonvegetarian | Record linkage with the California death certificate file, the National Death Index, and church records | Age, sex, and smoking status |
| Key et al (38), 1999 | The Heidelberg Study cohort | Germany | Mortality (Total) Mortality (IHD) Mortality (Cancer) | 185/ 1,757 29/ 1,757 23/ 1,757 | 48.0 | 21.3 | 44.6 | Mean 9.9 | FFQ | Vegetarian vs. nonvegetarian | Registrar's office of the last place of residence | Age, sex, and smoking status |
| Appleby et al (39), 2001 | Health Food Shoppers Study | United Kingdom | Mortality (Total) Mortality (Cancer) | 2,346/ 10,736 637/ | 45.4 | NA | 40.2 | Mean 18.7 | FFQ | Vegetarian vs. nonvegetarian | Record linkage with the National Health | Age, sex, smoking |

| Source | Study name | Region | Disease outcome | Case/ total number | Mean age (year) | Mean BMI (kg/m ²) | Men (%) | Follow up (year) | Diet assessment | Exposure | Disease ascertainment | Model adjustment |
|------------------------------------|--|--------------------------|--|--|-----------------------|-------------------------------------|------------|------------------------|--------------------|--|---|--|
| | | | Mortality (IHD) | 10,736 562/ 10,736 | | | | | | | Service Central Register | |
| Appleby et al (39), 2001 | Oxford Vegetarian Study | United Kingdom | Mortality (Total) Mortality (Cancer) Mortality (IHD) | 1,131/ 11,045 367/ 11,045 250/ 11,045 | 33.2 | 21.7 | 37.4 | Mean 17.6 | FFQ | Vegetarian vs. nonvegetarian | Record linkage with the National Health Service Central Register | Age, sex, smoking |
| Chang-Claude et al (40), 2005 | The German Vegetarian Study | Germany | Mortality (Total) Mortality (Cancer) Mortality (IHD) | 456/ 1,904 107/ 1,904 60/ 1,904 | ~45 | 20.9 | 45.1 | 21.0 | FFQ | Vegetarian vs. nonvegetarian | The vital status of the study participants was requested from the Registrar's Office at the last documented place of residence | Age, gender, smoking, activity, alcohol consumption, BMI, and education |
| Bamia et al (41), 2007 | EPIC-Elderly Study | 10 European countries | Mortality (Total) | 4,047/ 74,607 | ≥60 | NA | 32.9 | Maximum 11 | FFQ | Plant-based dietary score comparing extreme tertiles | Record linkage with population mortality registries and active follow-up | Age, sex, diagnosis of diabetes mellitus at baseline, waist-to-hip ratio, BMI, educational achievement, smoking status, physical activity at current work, physical activity score at leisure time, ethanol intake and total energy intake |
| Key et al (42), 2009 | EPIC-Oxford | United Kingdom | Mortality (Total) | 1,513/ 47,254 | 42.6 | 22.9 | 24.0 | Maximum 14.0 | FFQ | Vegetarian vs. meat eater | Record linkage with the United Kingdom's National Health Service Central Register | Age, sex, smoking, and alcohol consumption |
| Key et al (42), 2009 | EPIC-Oxford | United Kingdom | Mortality (IHD) | 213/ 47,254 | 42.6 | 22.9 | 24.0 | Maximum 14.0 | FFQ | Vegetarian vs. meat eater | Record linkage with the United Kingdom's National Health Service Central Register | Age, sex, smoking, and alcohol consumption |
| Orlich et al (43), 2013 | AHS-2 | United States and Canada | Mortality (Total) Mortality (Cancer) Mortality (CVD) | 2,570/ 73,308 706/ 73,308 987/ 73,308 | 56.9 | 27.1 | 33.6 | Mean 5.79 | FFQ | Vegan, lacto-ovo-vegetarian, pesco-vegetarian, semi-vegetarian vs. nonvegetarian | Record linkage to National Death Index | Age, race, smoking, exercise, personal income, educational level, marital status, alcohol, region, and sleep |
| Martínez-González et al (44), 2014 | Prevención con Dieta Mediterránea Study (PREDIMED) | Spain | Mortality (Total) Mortality (Cancer) Mortality (CVD) | 323/ 7,216 130/ 7,216 76/ 7,216 | 67.0 | 30.0 | 43.0 | Median 4.8 | FFQ | Provegetarian food pattern comparing extreme categories | Five physicians and one epidemiologist ascertained deaths from clinical registers on the basis of clinical records and death certificates | Sex, age, intervention group, smoking, leisure-time physical activity, total energy intake, educational level, and alcohol consumption |

| Source | Study name | Region | Disease outcome | Case/ total number | Mean age (year) | Mean BMI (kg/m ²) | Men (%) | Follow up (year) | Diet assessment | Exposure | Disease ascertainment | Model adjustment |
|----------------------------|---------------------|------------------|---|---|-----------------------|---|------------|------------------------|--------------------|--|---|---|
| Mihrshahi et al (45), 2016 | The 45 and Up Study | Australia | Mortality (Total) | 16,836/ 243,096 | 62.3 | BMI≥30 kg/m ² ; 22.2% | 46.7 | Mean 6.1 | FFQ | Vegetarian, pesco-vegetarian, semi-vegetarian vs. regular meat eater | Record linkage to the New South Wales Registry of Births, Deaths, and Marriages | Age, sex, education level, marital status, remoteness, country of birth and Socio-Economic Indexes for Areas, smoking status, physical activity and alcohol, cancer, hypertension, and cardiovascular and metabolic disease |
| Kim et al (46), 2018 | NHANES III | United States | Mortality (Total) Mortality (CVD) | 2,228/ 11,879 543/ 11,879 | 40.9 | BMI ≥30 kg/m ² ; 18.5% | 47.3 | Median 19.0 | FFQ | PDI, hPDI, uPDI per 10-unit increment, converted to comparing extreme quintiles | The National Center for Health Statistics tracked survey participants' vital status and cause of death with the use of probabilistic matching and by matching their records with the National Death Index records | Race, sex, age, total energy intake, education, federal poverty level, marital status, smoking status, physical activity, alcohol consumption, margarine intake, BMI, baseline hypertension, serum cholesterol, eGFR, and menopause (for women) |
| Baden et al (47), 2019 | NHS | United States | Mortality (Total) Mortality (CVD) Mortality (Cancer) | 10,686/ 49,407 2,046/ 49,407 3,091/ 49,407 | 63.5 | 24.1 | 0 | Maximum 16 | FFQ | 12-year change in PDI, hPDI, uPDI, comparing large increase (>10%) vs. no change for total mortality; 12- year change in PDI, hPDI, uPDI per 10 point increment for CVD mortality and cancer mortality and converted to comparing extreme quintiles (Change in adherence of plant-based diet) | Linkage with state vital statistics records and the National Death Index, or were reported by the participants' families and the U.S. postal system | Age, initial plant-based diet index score, race, family history of myocardial infarction, diabetes, or cancer, aspirin use, multivitamins use, initial BMI, menopausal status and hormone use, smoking status, smoking, physical activity, total energy intake, alcohol consumption, margarine intake, weight change, history of hypertension, hypercholesterolemia, or type 2 diabetes, antihypertensive medication use, and cholesterol- lowering medication use. |
| Baden et al (47), 2019 | HPFS | United States | Mortality (Total) Mortality (CVD) Mortality (Cancer) | 6,490/ 25,907 1,872/ 25,907 1,772/ 25,907 | 62.5 | 25.1 | 100 | Maximum 16 | FFQ | 12-year change in PDI, hPDI, uPDI, comparing large increase (>10%) vs. no change (Change in adherence of plant-based diet) | Linkage with state vital statistics records and the National Death Index, or were reported by the participants' families and the U.S. postal system | Age, initial plant-based diet index score, race, family history of myocardial infarction, diabetes, or cancer, aspirin use, multivitamins use, initial BMI, smoking status, smoking, physical activity, total energy intake, alcohol consumption, margarine intake, |

| Source | Study name | Region | Disease outcome | Case/ total number | Mean age (year) | Mean BMI (kg/m ²) | Men (%) | Follow up (year) | Diet assessment | Exposure | Disease ascertainment | Model adjustment |
|-------------------------|---|---------------|--|--|-----------------------|-------------------------------------|------------|------------------------|--------------------|---|---|--|
| | | | | | | | | | | | | weight change, history of hypertension, hypercholesterolemia, or type 2 diabetes, antihypertensive medication use, and cholesterol-lowering medication use. |
| Kim et al (19), 2019 | ARIC | United States | Mortality (Total) Mortality (CVD) | 5,436/ 12,168 1,565/ 12,168 | 53.8 | Obesity (20.7%) | 44.1 | Median 25 | FFQ | PDI, hPDI, uPDI, provegetarian diet index comparing extreme quintiles | Ascertained through annual telephone calls with participants or proxies, active surveillance of local hospital discharge records and state death records, and linkage to the National Death Index | Age, sex, race-center, total energy intake, education, smoking status, physical activity, alcohol consumption, and margarine consumption |
| Anyene et al (48), 2021 | The Pathways Study | United States | Mortality (Total) Mortality (Breast cancer) | 653/ 3,646 323/ 3,646 | 60.0 | 28.0 | 0 | Median 9.51 | FFQ | PDI, hPDI, uPDI per 10-unit increment, and converted to comparing extreme quintiles | A combination of follow-up health status questionnaires and Kaiser Permanente Northern California electronic medical record searches | Age at diagnosis, total energy intake, physical activity, race/ethnicity, education, menopausal status, and smoking status |
| Kim et al (49), 2021 | Korean Genome and Epidemiology Study_Health Examinees | South Korea | Mortality (Total) Mortality (CVD) Mortality (Cancer) | 3,074/118,577 (Total) 447/118,577 (CVD) 1,515/118,577 (Cancer) | 52.7 | 23.9 | 34.9 | Maximum 12 | FFQ | PDI, hPDI, uPDI, comparing extreme quintiles | Deaths were ascertained through the death certificate database of the National Statistical Office from baseline to December 31, 2019, classified using ICD-10. | Age, sex, education, smoking status, alcohol consumption, energy intake, physical activity, body mass index, and disease history |
| Lo et al (50), 2021 | Mr. OS and Ms. OS Study | Hong Kong | Mortality (Total) Mortality (CVD) Mortality (Cancer) | 1,370/3,991 (Total) 314/3,991 (CVD) 469/3,991 (Cancer) | 72.5 | 23.7 | 50 | Median 11.1 | FFQ | Portfolio Diet comparing extreme quartiles | Death Registry of the Department of Health of HK, classified according to ICD-10 | Sex, age, dietary energy, body mass index, physical activity, systolic blood pressure, medical history (diabetes, hypertension, stroke, heart attack, angina, congestive heart failure or cancer), smoking habit, alcohol drinking, education level. |
| Ratjen et al (51), 2021 | The biobank popgen | Germany | Mortality (Total) | 204/ 1,404 | 69.0 | 26.2 | 56 | Median 7.0 | FFQ | PDI, hPDI, uPDI, comparing extreme quartiles | Record linkage with the population registries | Sex, age at diet assessment, BMI, physical activity, survival time from colorectal cancer diagnosis until diet assessment, tumor location, metastases, other cancer, type of therapy, smoking status, |

| Source | Study name | Region | Disease outcome | Case/ total number | Mean age (year) | Mean BMI (kg/m ²) | Men (%) | Follow up (year) | Diet assessment | Exposure | Disease ascertainment | Model adjustment |
|-----------------------------------|---|----------------|--|--|-----------------------|-------------------------------------|------------|--|----------------------------|--|---|--|
| Petermann-Rocha et al (25), 2021 | UK Biobank | United Kingdom | Mortality (CVD) | 6,580/ 422,791 | 56.4 | 27.3 | 44.6 | Median 9.3 | 24-hour dietary recall | Vegetarians, fish eaters, fish, and poultry eaters vs. meat-eaters | Record linkage to registries | alcohol intake, total energy intake, time × age, time × BMI, and time × metastases |
| Chen et al (52), 2022 (c) | Chinese Longitudinal Healthy Longevity Survey (CLHLS) | China | Mortality (Total) | 8,937/13,154 | 86.9 | 20.3 | 42.6 | 5.7 | FFQ | PDI, hPDI, uPDI, comparing extreme quintiles | Information on the death status and indicators of the predeath health status of participants was collected via interviews with their close family members. Date of death was documented according to official death certificate if available, or otherwise, from the close relatives of the participant or residents committee. | Age, sex, ethnicity, residential area, marital status, household income, education, smoking, alcohol intake, physical activity, and BMI |
| Delgado-Velandia et al (53), 2022 | Nutrition and Cardiovascular Risk in Spain (ENRICA) | Spain | Mortality (Total) Mortality (CVD) | 699/11,825 (Total) 157/11,825 (CVD) | 46.9 | 26.9 | 49.6 | Median 10.9 (Total), Median 9.8 (CVD) | Electronic diet history | hPDI, uPDI, comparing extreme quintiles | Record linkage to the National Death Index of Spain, classified according to ICD-10 | Age, sex, education, smoking, BMI, energy intake, alcohol consumption, physical activity, number of chronic diseases, and number of medications taken |
| Li et al (54), 2022 | NHANES | United States | Mortality (Total) Mortality (Cancer) Mortality (CVD) | 4,904/ 40,074 1,068/ 40,074 1,029/ 40,074 | 47.3 | 28.5 | 48.0 | Median 7.8 | 24-hour dietary recall | PDI, hPDI, uPDI, comparing extreme quintiles | Record linkage to the National Death Index | Sex, age, total energy intake, race/ethnicity, education, marital status, ratio of family income to poverty, physical activity, smoking, drinking, BMI, diabetes, hypertension, other CVDs, and cancer |
| Wang et al (55), 2022 | The VA Million Veteran Program | United States | Mortality (Total) Mortality (CVD) Mortality (Cancer) | 31,136/315,919 9 (Total) 9,751/315,919 (CVD) 9,510/315,919 (Cancer) | 65.5 | 28.7 | 65.7 | Mean 4 | SFFQ | PDI, hPDI, uPDI, comparing extreme deciles | Record linkage to the National Death Index, classified according to ICD-10-CM | Age, sex, race, education, income, marriage, smoking, alcohol consumption, frequency of exercise vigorously, total energy intake, BMI, histories of diabetes, hypertension, hypercholesterolemia, cancer and CVD at baseline |

| Source | Study name | Region | Disease outcome | Case/ total number | Mean age (year) | Mean BMI (kg/m ²) | Men (%) | Follow up (year) | Diet assessment | Exposure | Disease ascertainment | Model adjustment |
|----------------------------|-------------|-----------------------|---|--|-----------------------|-------------------------------------|------------|------------------------|--------------------|--------------------------------------|---|--|
| Shan et al (56), 2023 | NHS | United States | Mortality (Total) Mortality (CVD) Mortality (Heart disease) Mortality (Stroke) Mortality (Cancer) Mortality (Respiratory disease) Mortality (Neurodegenerati ve disease) | Total: 31,263/75,230 CVD: 6,128/75,230 Heart disease: 4,330/75,230 Stroke: 1,798/75,230 Cancer: 8,733/75,230 Respiratory disease: 2,491/75,230 Neurodegener ative disease: 5,004/75,230 | 50.2 | 24.9 | 0 | Maximu m 36 | FFQ | hPDI, comparing extreme quintiles | Self-reported, confirmed by medical records | Age, calendar year, race, marriage status, living status, family history of MI, family history of diabetes, family history of cancer, menopaUnited Statesl status (in women), multivitamin use, aspirin use, total energy intake, smoking, alcohol consumption, history of hypertension, history of hypercholesterolemia, and BMI |
| Shan et al (56), 2023 | HPFS | United States | Mortality (Total) Mortality (CVD) Mortality (Heart disease) Mortality (Stroke) Mortality (Cancer) Mortality (Respiratory disease) Mortality (Neurodegenerati ve disease) | Total: 22,900/44,085 CVD: 6,641/44,085 Heart disease: 5,386/44,085 Stroke: 1,255/44,085 Cancer: 5,710/44,085 Respiratory disease: 1,738/44,085 Neurodegener ative disease: 2,101/44,085 | 53.3 | 24.0 | 100 | Maximu m 36 | FFQ | hPDI, comparing extreme quintiles | Self-reported, confirmed by medical records | Age, calendar year, race, marriage status, living status, family history of MI, family history of diabetes, family history of cancer, multivitamin use, aspirin use, total energy intake, smoking, alcohol consumption, history of hypertension, history of hypercholesterolemia, and BMI |
| Fraser et al (57), 1999 | AHS | United States | Cancer (Breast) Cancer (Colon) Cancer (Lung) Cancer (Prostate) Cancer (Uterine) | 128/ 34,198 107/ 34,198 45/ 34,198 127/ 34,198 116/ 34,198 | 54.0 | 25.0 | 40.5 | 6 | FFQ | Vegetarian vs. Nonvegetarian | Record linkage to population-based tumor registries, state death tapes and the National Death Index | Age, sex, and smoking (for lung cancer) |
| Key et al (58), 2009 | EPIC-Oxford | United Kingdo m | Cancer (Total) Cancer (Breast) Cancer (Colorectal) | 2,179/ 63,550 734/ 63,550 | 43.4 | 23.0 | 23.2 | Maximu m 12.0 | FFQ | Vegetarian vs. Nonvegetarian | Record linkage with the United Kingdom's National Health | Smoking |

| Source | Study name | Region | Disease outcome | Case/ total number | Mean age (year) | Mean BMI (kg/m ²) | Men (%) | Follow up (year) | Diet assessment | Exposure | Disease ascertainment | Model adjustment |
|--|------------|-----------------------------------|------------------------|-----------------------|-----------------------|-------------------------------------|------------|------------------------|--------------------|---|---|--|
| | | | Cancer (Lung) | 228/ | | | | | | | Service Central | |
| | | | Cancer (Ovarian) | 63,550 | | | | | | | Register | |
| | | | Cancer (Prostate) | 88/ | | | | | | | | |
| | | | | 63,550 | | | | | | | | |
| | | | | 92/ | | | | | | | | |
| | | | | 63,550 | | | | | | | | |
| | | | | 183/ | | | | | | | | |
| | | | | 63,550 | | | | | | | | |
| Cade et al (59), 2010 | UKWCS | United Kingdom | Cancer (Breast) | 783/ 35,372 | 52.6 | 24.5 | 0 | Mean 9.0 | FFQ | Vegetarian, fish eater, poultry eater, vs. red meat eater | Subjects were flagged with the National Health Service Central Register for cancer and death notification | Age, energy intake, menopausal status, calorie adjusted fat, BMI, physical activity, oral contraception pill use, hormone replacement therapy use, smoking status, parity, age at menarche, ethanol, total days breast feeding, socioeconomic class, and level of education |
| Tantamango- Bartley et al (60), 2013 | AHS-2 | United States and Canada | Cancer (Total) | 2,939/ 69,120 | ≥30 | 27.2 | 36.3 | 4.14 | FFQ | Vegan, lactoovo- vegetarian, pesco-vegetarian, semi-vegetarian and non- vegetarian | Record linkage with state tumor registries | Race, family history of cancer, BMI, education, smoking, alcohol, age at menarche, pregnancies, breastfeeding, oral contraceptives, hormone replacement therapy, and menopause status |
| Gilting et al (61), 2015 | NLCS-MIC | The Netherlands | Cancer (Colorectal) | 437/ 10,210 | 61.3 | 24.7 | 53.5 | 20.3 | FFQ | Vegetarians, pescetarians, 1 day/week meat consumers, 2-5 day/week meat consumers vs. 6- 7 day/week meat consumers | Repeated record linkage to the Netherlands Cancer Registry, the Dutch Pathology Registry, and the cause of death registry (Statistics Netherlands) | Age, sex, total energy intake, cigarette smoking, alcohol consumption, BMI, non- occupational physical activity, and level of education |
| Orlich et al (62), 2015 | AHS-2 | United States and Canada | Cancer (Colorectal) | 490/ 77,659 | 57.1 | 27.2 | 34.5 | Mean 7.3 | FFQ | Vegan, lacto- ovo-vegetarian, pesco-vegetarian, semi-vegetarian vs. Nonvegetarian | Record linkage with state cancer registries | Age, race, sex, education, moderate or vigorous exercise, smoking, alcohol use, family history of colorectal cancer, history of peptic ulcer, history of inflammatory bowel disease, treatment for diabetes mellitus within the past year, used aspirin at least weekly at least 2 of the past 5 years, used statins at least 2 of the past 5 years, prior colonoscopy or flexible sigmoidoscopy, supplemental calcium use, supplemental vitamin D, dietary energy, and hormone therapy among menopausal women, BMI, and fiber intake |

| Source | Study name | Region | Disease outcome | Case/ total number | Mean age (year) | Mean BMI (kg/m ²) | Men (%) | Follow up (year) | Diet assessment | Exposure | Disease ascertainment | Model adjustment |
|---|------------|--------------------------|---------------------|-----------------------|-----------------------|-------------------------------------|------------|------------------------|--------------------|--|--|---|
| Gilsing et al (63), 2016 | NLCS-MIC | The Netherlands | Cancer (Breast) | 312/ 5,218 | 61.3 | 24.7 | 0 | 20.3 | FFQ | Vegetarian vs. nonvegetarian | Repeated record linkage to the Netherlands Cancer Registry, the Dutch Pathology Registry, and the cause of death registry (Statistics Netherlands) | Age, total energy intake, cigarette smoking, frequency of smoking, duration of smoking, alcohol consumption, BMI, non-occupational physical activity, and level of education |
| Gilsing et al (63), 2016 | NLCS-MIC | The Netherlands | Cancer (Lung) | 279/ 9,773 | 61.3 | 24.7 | 45.0 | 20.3 | FFQ | Vegetarian vs. nonvegetarian | Repeated record linkage to the Netherlands Cancer Registry, the Dutch Pathology Registry, and the cause of death registry (Statistics Netherlands) | Age, total energy intake, cigarette smoking, frequency of smoking, duration of smoking, alcohol consumption, BMI, non-occupational physical activity, and level of education |
| Gilsing et al (63), 2016 | NLCS-MIC | The Netherlands | Cancer (Prostate) | 399/ 4,864 | 61.3 | 24.7 | 100 | 20.3 | FFQ | Vegetarian vs. nonvegetarian | Repeated record linkage to the Netherlands Cancer Registry, the Dutch Pathology Registry, and the cause of death registry (Statistics Netherlands) | Age, total energy intake, cigarette smoking, frequency of smoking, duration of smoking, alcohol consumption, BMI, non-occupational physical activity, and level of education |
| Tantamango-Bartley et al (64), 2016 | AHS-2 | United States and Canada | Cancer (Prostate) | 1,079/ 27,188 | 66.0 | BMI>30 kg/m ² ; 20% | 100 | Mean 7.8 | FFQ | Vegan, lacto-ovo-vegetarian, pesco-vegetarian, semi-vegetarian vs. nonvegetarian | Linkage to state cancer registries | Age, race, family history of prostate cancer, education, screening for prostate cancer, total calorie, and BMI |
| Pennicook-Sawyers et al (65), 2016 | AHS-2 | United States and Canada | Cancer (Breast) | 892/ 50,404 | 35-110 | 27.5 | 0 | Mean 7.8 | FFQ | Vegan, lactoovo-vegetarian, pesco-vegetarian, semi-vegetarian and non-vegetarian | Record linkage with forty-eight state cancer registries | Race, height, physical activity, family history of cancer, mammography in the last 2 years after age 42 years, age at menopause, age at menarche, birth control pills, hormone replacement therapy, age at first child, number of children, breastfeeding, educational level, smoking, alcohol, and BMI |
| Rada-Fernandez de Jauregui et al (66), 2018 | UKWCS | United Kingdom | Cancer (Colorectal) | 462/ 32,147 | 52.0 | 24.4 | 0 | Mean 17.2 | FFQ | Red meat free eaters vs. red meat eaters | Record linkage of cancer identification codes from the central register of National Health Service | Age, BMI, energy intake, physical activity, smoking status, family history of CRC in a first degree relative and socio-economic status |

| Source | Study name | Region | Disease outcome | Case/ total number | Mean age (year) | Mean BMI (kg/m ²) | Men (%) | Follow up (year) | Diet assessment | Exposure | Disease ascertainment | Model adjustment |
|------------------------------------|--------------------------|---------------|---|---|-----------------------|-------------------------------------|------------|------------------------|---------------------------|--|--|--|
| Kane-Diallo et al (67), 2018 | The NutriNet-Santé study | France | Cancer (Breast) Cancer (Digestive) Cancer (Lung) Cancer (Prostate) Cancer (Total) | 487/ 42,544 198/ 42,544 68/ 42,544 243/ 42,544 1,591/ 42,544 | 56.9 | 24.7 | 27.3 | Median 4.3 | 24-hour dietary recall | Pro plant-based dietary score comparing extreme tertiles | Self-reported, confirmed by medical records | Age, sex, energy intake without alcohol, number of 24-hr dietary records, smoking status, educational level, physical activity, height, BMI, alcohol intake, family history of cancer, lipids intake, and for breast cancer analyses, hormone replacement therapy, number of children, and contraception use |
| Leone et al (68), 2020 | SUN | Spain | Cancer (Skin, basal cell carcinoma) | 101/ 505 | 48.0 | 44.6 | 24.0 | Maximum 20.0 | FFQ | Pro-vegetarian dietary pattern comparing extreme quintiles | Self-reported confirmation of medical records | Age, height, smoking, physical activity, recruitment year, total energy intake, family history of melanoma, use of sunscreen during sun exposure, sunburns during childhood and adolescence, number of sunburns during adolescence, and presence of freckles |
| Romanos-Nanclares et al (69), 2020 | SUN | Spain | Cancer (Breast) | 101/ 10,812 | 34.6 | 22.2 | 0 | Median 11.5 | FFQ | Provegetarian food pattern, healthful provegetarian food pattern, and unhealthful provegetarian food pattern comparing extreme tertiles | Self-reported with confirmation of follow-up questionnaire and medical records | Height, family history of breast cancer, smoking status, physical activity, alcohol intake, BMI, age at the time of menarche, menopause, number of pregnancies >6 months, pregnancy before the age of 30 years, months of breastfeeding, use of hormone replacement therapy and its duration, years at university, and total energy intake |
| Anyene et al (48), 2021 | The Pathways Study | United States | Breast cancer recurrence | 461/ 3,646 | 60.0 | 28.0 | 0 | Median 9.2 | FFQ | PDI, hPDI, uPDI per 10-unit increment | A combination of follow-up health status questionnaires and Kaiser Permanente Northern California electronic medical record searches | Age at diagnosis, total energy intake, physical activity, race/ethnicity, education, menopausal status, and smoking status |
| Romanos-Nanclares et al (70), 2021 | NHS | United States | Cancer (Breast) | 8,220/ 76,690 | 50.9 | 25.1 | 0 | Maximum 32.0 | FFQ | PDI, hPDI, uPDI, comparing extreme quintiles | Self-reported, confirmed by medical records | Race, age at menarche, age at menopause, postmenopausal hormone use, oral contraceptive use history, parity and age at first birth, breastfeeding history, family history of breast cancer and benign breast disease, height, alcohol intake, total caloric intake, physical activity, BMI at age 18 years and socioeconomic status |

| Source | Study name | Region | Disease outcome | Case/ total number | Mean age (year) | Mean BMI (kg/m ²) | Men (%) | Follow up (year) | Diet assessment | Exposure | Disease ascertainment | Model adjustment |
|------------------------------------|--------------------------|---------------|-----------------------------------|--|----------------------------|-------------------------------------|------------|------------------------|--------------------|--|---|---|
| Romanos-Nanclares et al (70), 2021 | NHSII | United States | Cancer (Breast) | 4,262/ 93,295 | 36.7 | 24.4 | 0 | Maximum 26.0 | FFQ | PDI, hPDI, uPDI, comparing extreme quintiles | Self-reported, confirmed by medical records | Race, age at menarche, age at menopause, postmenopausal hormone use, oral contraceptive use history, parity and age at first birth, breastfeeding history, family history of breast cancer and benign breast disease, height, alcohol intake, total caloric intake, physical activity, BMI at age 18 years and socioeconomic status |
| Kim et al (71), 2022 | Multiethnic Cohort Study | United States | Cancer (Colorectal) | 2,582/79,952 (Men) 2,394/93,475 (Women) | 60.0 (Men) 59.3 (Women) | 26.6 (Men) 26.4 (Women) | 46.1 | Mean 19.2 | QFFQ | PDI, hPDI, uPDI, comparing extreme quintiles | Incident colorectal cancer cases were identified by linkage to the statewide Surveillance, Epidemiology, and End Results Program tumor registries in Hawaii and California. Deaths were identified by linkage to death certificate files in both states and the National Death Index. | Age at cohort entry, family history of colorectal cancer, history of colorectal polyp, BMI, smoking, multivitamin use, nonsteroidal anti-inflammatory drug use, physical activity, menopausal hormone therapy use for women only, alcohol consumption, and total energy intake |
| Loeb et al (72), 2022 | HPFS | United States | Cancer (Prostate) | 6,655/47,239 | 65 | 22 | 100 | Median 20.7 | FFQ | PDI, hPDI, comparing extreme quintiles | Biennial questionnaires, medical records and pathology reports. | Age and time period, race, height, BMI, BMI at age 21, smoking status, family history of prostate cancer, PSA test in previous cycle, PSA testing in >50% of previous cycles, multivitamin use, vitamin E supplement use, alcohol intake, physical activity, aspirin use, anti-cholesterol medication, diabetes, total energy intake. |
| Kim et al (73), 2023 (a) | Multiethnic Cohort Study | United States | Cancer (Hepatocellular carcinoma) | 772/170,321 | 59.5 | 26.5 | 46.3 | Mean 19.6 | FFQ | PDI, hPDI, uPDI, comparing extreme quintiles | Incident HCC cases were ascertained by linkage to the statewide Surveillance, Epidemiology and End Results Program tumor registries in Hawaii and California. | Race and ethnicity, sex, age at cohort entry, family history of liver cancer, history of diabetes, BMI, cigarette smoking, alcohol consumption, and total energy intake. |
| Kim et al (74), 2023 (b) | NHS | United States | Cancer (Digestive system) | Digestive system 3,178/74,496 | 65.0 | 25.5 | 0 | Maximum 34 | FFQ | PDI, hPDI, uPDI, per 10 points increment | Self-reported, confirmed by medical records | Age, calendar year, cohort, race, BMI, physical activity, smoking, alcohol consumption, family history of cancer, personal history |

| Source | Study name | Region | Disease outcome | Case/ total number | Mean age (year) | Mean BMI (kg/m ²) | Men (%) | Follow up (year) | Diet assessment | Exposure | Disease ascertainment | Model adjustment |
|-----------------------------|---|------------------|---------------------------------|--------------------------------------|-----------------------|-------------------------------------|------------|------------------------|-------------------------------|--|---|--|
| | | | Cancer (Colorectal) | Colorectal: 1,883/74,496 | | | | | | | | of diabetes, current multivitamin use, regular aspirin use, regular NSAID use, menopaUnited Statesl |
| | | | Cancer (Pancreatic) | Pancreatic: 554/74,496 | | | | | | | | status (in women), total energy intake, and calcium supplement |
| | | | Cancer (Liver) | Liver: 86/74,496 | | | | | | | | intake. For liver and stomach |
| | | | Cancer (Stomach) | Stomach: 136/74,496 | | | | | | | | cancer, the models were adjusted for age only. |
| Kim et al (74), 2023 (b) | NHSII | United States | Cancer (Digestive system) | Digestive system: 714/91,705 | 49.3 | 25.5 | 0 | Maximu m 26 | FFQ | PDI, hPDI, uPDI, per 10 points increment | Self-reported, confirmed by medical records | Age, calendar year, cohort, race, BMI, physical activity, smoking, alcohol consumption, family history of cancer, personal history of diabetes, current multivitamin use, regular aspirin use, regular NSAID use, menopausal status (in women), total energy intake, and calcium supplement intake. For liver and stomach cancer, the models were adjusted for age only. |
| | | | Cancer (Colorectal) | Colorectal: 464/91,705 | | | | | | | | history of cancer, personal history of diabetes, current multivitamin use, regular aspirin use, regular NSAID use, menopausal status (in women), total energy intake, and calcium supplement intake. For liver and stomach cancer, the models were adjusted for age only. |
| | | | Cancer (Pancreatic) | Pancreatic: 78/91,705 | | | | | | | | use, regular aspirin use, regular NSAID use, menopausal status (in women), total energy intake, and calcium supplement intake. For liver and stomach cancer, the models were adjusted for age only. |
| | | | Cancer (Liver) | Liver: 15/91,705 | | | | | | | | and calcium supplement intake. For liver and stomach cancer, the models were adjusted for age only. |
| | | | Cancer (Stomach) | Stomach: 14/91,705 | | | | | | | | models were adjusted for age only. |
| Kim et al (74), 2023 (b) | HPFS | United States | Cancer (Digestive system) | Digestive system: 2,626/45,472 | 65.4 | 25.5 | 100 | Maximu m 30 | FFQ | PDI, hPDI, uPDI, per 10 points increment | Self-reported, confirmed by medical records | Age, calendar year, cohort, race, BMI, physical activity, smoking, alcohol consumption, family history of cancer, personal history of diabetes, current multivitamin use, regular aspirin use, regular NSAID use, total energy intake, and calcium supplement intake. For liver and stomach cancer, the models were adjusted for age only. |
| | | | Cancer (Colorectal) | Colorectal: 1,447/45,472 | | | | | | | | history of cancer, personal history of diabetes, current multivitamin use, regular aspirin use, regular NSAID use, total energy intake, and calcium supplement intake. For liver and stomach cancer, the models were adjusted for age only. |
| | | | Cancer (Pancreatic) | Pancreatic: 494/45,472 | | | | | | | | and calcium supplement intake. For liver and stomach cancer, the models were adjusted for age only. |
| | | | Cancer (Liver) | Liver: 74/45,472 | | | | | | | | models were adjusted for age only. |
| | | | Cancer (Stomach) | Stomach: 169/45,472 | | | | | | | | models were adjusted for age only. |
| Shah et al (75), 2022 | E3N | France | Cancer (Breast) | 3,968/65,574 | 52.9 | 22.9 | 0 | Mean 21 | FFQ | PDI, hPDI, uPDI, comparing extreme quintiles | Self-reported, confirmed through pathological reports | Age, birth cohort, education, physical activity, smoking, history of breast cancer, breastfeeding, age at menarche, age at first full-term birth, past history of benign breast disease, ever use of the contraceptive pill, ever use of menopausal hormone therapy, mammography in the last follow-up cycle, BMI, energy intake, and alcohol consumption |
| Zhong et al (76), 2023 | Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial | United States | Cancer (Pancreatic) | 421/101,748 | 65.5 | 27.2 | 48.6 | Mean 8.9 | Diet history questionnaire | PDI, hPDI, uPDI, comparing extreme quartiles | Self-reported, confirmed by medical records | Age, sex, race, BMI, alcohol consumption, smoking, family history of pancreatic cancer, and history of diabetes; energy intake wasadjusted for food consumption |

| Source | Study name | Region | Disease outcome | Case/ total number | Mean age (year) | Mean BMI (kg/m ²) | Men (%) | Follow up (year) | Diet assessment | Exposure | Disease ascertainment | Model adjustment and nutrient intakes before formal analyses |
|--------|------------|--------|-----------------|-----------------------|-----------------------|-------------------------------------|------------|------------------------|--------------------|----------|--------------------------|--|
|--------|------------|--------|-----------------|-----------------------|-----------------------|-------------------------------------|------------|------------------------|--------------------|----------|--------------------------|--|

Abbreviations: AHS, Adventist Health Study; AHS-2, Adventist Health Study-2; AMS, Adventist Mortality Study; APDQS, A Priori Diet Quality Score; ARIC, Atherosclerosis Risk in Communities; BMI, body mass index; CHD, coronary heart disease; CRC, colorectal cancer; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; EPIC, European Prospective Investigation into Cancer and Nutrition; FFQ, food frequency questionnaire; HbA1c, hemoglobin A1c; hPDI, Healthful Plant-Based Diet Index; HPFS, Health Professionals Follow-up Study; IHD, ischemic heart disease; MI, myocardial infarction; NHANES, National Health and Nutrition Examination Survey; NHS, Nurses' Health Study; NHSII, Nurses' Health Study II; NLCS-MIC, Netherlands Cohort Study-Meat Investigation Cohort; PDI, Plant-Based Diet Index; SUN, Seguimiento Universidad de Navarra cohort; T2D, type 2 diabetes; UKWCS, United Kingdom Women's Cohort Study; uPDI, Unhealthful Plant-Based Diet Index; Y, year; WHI, Women's Health Initiative Prospective Cohort Study; UK, United Kingdom.

Supplemental Table S4. Assessment of Individual Study Bias and Study Quality.

| Source | Criteria | Yes | No | Cannot determine, not applicable |
|----------------------------|--|-----|----|-------------------------------------|
| Vang et al (1), 2008 | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | | X | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | | X | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | | X | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | | | X |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | | X | |
| Total | | 8 | | |
| Tonstad et al (2), 2013 | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | | X | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | | X | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | | | X |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | X | | |
| Total | | 10 | | |

| Source | Criteria | Cannot determine, not applicable | | |
|---|--|----------------------------------|----|--|
| | | Yes | No | |
| Satija et al (3), 2016 (NHS, NHSII, HPFS) | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | X | | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | X | | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | X | | |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | X | | |
| Total | | 13 | | |
| Chen et al (4), 2018 (Rotterdam Study I, II, III) | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | | X | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | | X | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | | X | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | X | | |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | X | | |
| Total | | 10 | | |
| Chen et al (5), 2018 | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |

| Source | Criteria | Yes | No | Cannot determine, not applicable | |
|--|--|---|----|-------------------------------------|--|
| (Singapore Chinese Health Study) | 3. Was the participation rate of eligible persons at least 50%? | X | | | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | | |
| | 10. Was the exposure(s) assessed more than once over time? | | X | | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | | |
| | 13. Was loss to follow-up after baseline 20% or less? | X | | | |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | X | | | |
| | Total | | 12 | | |
| | Chiu et al (6), 2018 | 1. Was the research question or objective in this paper clearly stated? | X | | |
| 2. Was the study population clearly specified and defined? | | X | | | |
| 3. Was the participation rate of eligible persons at least 50%? | | X | | | |
| 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | | X | | | |
| 5. Was a sample size justification, power description, or variance and effect estimates provided? | | | X | | |
| 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | | X | | | |
| 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | | X | | | |
| 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | | | | X | |
| 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | | X | | | |
| 10. Was the exposure(s) assessed more than once over time? | | X | | | |
| 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | | X | | | |
| 12. Were the outcome assessors blinded to the exposure status of participants? | | X | | | |
| 13. Was loss to follow-up after baseline 20% or less? | | | | X | |
| 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | | X | | | |
| Total | | 11 | | | |
| Papier et al (7), 2019 | 1. Was the research question or objective in this paper clearly stated? | X | | | |
| | 2. Was the study population clearly specified and defined? | X | | | |
| | 3. Was the participation rate of eligible persons at least 50%? | X | | | |

| Source | Criteria | Yes | No | Cannot determine, not applicable |
|---|--|-----|----|-------------------------------------|
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | | | X |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | | X | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | X | | |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | X | | |
| | Total | 11 | | |
| Choi et al (8), 2020 | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | | X | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | X | | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | | X | |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | X | | |
| | Total | 11 | | |
| Chen et al (9), 2021 (NHS, NHSII, HPFS) | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | X | | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |

| Source | Criteria | Yes | No | Cannot determine, not applicable |
|-----------------------------|--|-----|----|-------------------------------------|
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | X | | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | X | | |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | X | | |
| | Total | 13 | | |
| Flores et al (10), 2021 | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | X | | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | | X | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | X | | |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | X | | |
| | Total | 12 | | |
| Laouali et al (11), 2021 | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | X | | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |

| Source | Criteria | | | Cannot determine, not applicable |
|-------------------------------------|--|-----|----|-------------------------------------|
| | | Yes | No | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | | X | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | X | | |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | X | | |
| | Total | 12 | | |
| Yang et al (12), 2021 | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | X | | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | | X | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | | | X |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | X | | |
| | Total | 11 | | |
| Bhupathiraju et al (13), 2022 | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | X | | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |

| Source | Criteria | | | Cannot determine, not applicable |
|---|--|-----|----|-------------------------------------|
| | | Yes | No | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | X | |
| | 10. Was the exposure(s) assessed more than once over time? | | | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | X | | |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | X | | |
| | Total | 12 | | |
| Chen et al (14), 2022 (China Nutrition and Health Survey) | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | X | | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | X | | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | | X | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | | X | |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | X | | |
| | Total | 11 | | |
| Kim and Giovannucci (15), 2022 | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | X | | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | |

| Source | Criteria | Yes | No | Cannot determine, not applicable |
|----------------------------------|--|-----|----|-------------------------------------|
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | X | | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | X | | |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | X | | |
| | Total | 13 | | |
| Glenn et al (16), 2023 | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | X | | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | X | | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | X | | |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | X | | |
| | Total | 13 | | |
| Zhang et al (17), 2023 (a) | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | X | | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | | X | |

| Source | Criteria | | | Cannot determine, not applicable |
|--|--|-----|----|-------------------------------------|
| | | Yes | No | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | X | | |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | X | | |
| | Total | 12 | | |
| Satija et al (18), 2017 (NHS, NHSII, HPFS) | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | X | | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | X | | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | X | | |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | X | | |
| | Total | 13 | | |
| Kim et al (19), 2019 | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | X | | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | X | | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |

| Source | Criteria | | | Cannot determine, not applicable |
|--------------------------|--|-----|----|-------------------------------------|
| | | Yes | No | |
| | 13. Was loss to follow-up after baseline 20% or less? | | | X |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | X | | |
| | Total | 12 | | |
| Tong et al (20), 2019 | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | X | | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | X | | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | X | | |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | X | | |
| | Total | 13 | | |
| Chiu et al (21), 2020 | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | X | | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | | | X |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | | X | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | | | X |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | X | | |

| Source | Criteria | Yes | No | Cannot determine, not applicable |
|---|--|-----|----|-------------------------------------|
| | | | | |
| | Total | | | 10 |
| Shan et al (22), 2020 (NHS, NHSII, HPFS) | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | X | | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | X | | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | X | | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | X | | |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | X | | |
| | Total | | | 14 |
| Baden et al (23), 2021 (NHS, NHSII, HPFS) | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | X | | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | X | | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | X | | |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | X | | |
| | Total | | | 13 |

| Source | Criteria | Cannot determine, not applicable | | |
|----------------------------------|--|----------------------------------|----|---|
| | | Yes | No | |
| Glenn et al (24), 2021 | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | X | | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | X | | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | | | X |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | X | | |
| Total | | 12 | | |
| Petermann-Rocha et al (25), 2021 | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | X | | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | | | X |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | | X | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | | | X |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | X | | |
| Total | | 10 | | |
| Chen et al (26), 2022 | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |

| Source | Criteria | Yes | No | Cannot determine, not applicable | |
|------------------------|--|-----|----|-------------------------------------|--|
| (HCHS/SOL) | 3. Was the participation rate of eligible persons at least 50%? | X | | | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | | | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | | | | |
| | 10. Was the exposure(s) assessed more than once over time? | X | | | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | | |
| | 13. Was loss to follow-up after baseline 20% or less? | X | X | | |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | | | | |
| | Total | | X | | |
| | | | 12 | | |
| Choi et al (27), 2022 | 1. Was the research question or objective in this paper clearly stated? | X | | | |
| | 2. Was the study population clearly specified and defined? | X | | | |
| | 3. Was the participation rate of eligible persons at least 50%? | X | | | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | | |
| | 10. Was the exposure(s) assessed more than once over time? | X | | | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | | |
| | 13. Was loss to follow-up after baseline 20% or less? | X | | | |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | X | | | |
| Total | | 13 | | | |
| Ibsen et al (28), 2022 | 1. Was the research question or objective in this paper clearly stated? | X | | | |
| | 2. Was the study population clearly specified and defined? | X | | | |
| | 3. Was the participation rate of eligible persons at least 50%? | | X | | |

| Source | Criteria | Yes | No | Cannot determine, not applicable |
|---------------------------|--|-----|----|-------------------------------------|
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | | X | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | X | | |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | X | | |
| | Total | 11 | | |
| Kouvari et al (29), 2022 | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | X | | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | X | | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | | X | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | X | | |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | X | | |
| | Total | 13 | | |
| Lazarova et al (30), 2022 | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | | X | |
| | 3. Was the participation rate of eligible persons at least 50%? | | X | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | | X | |

| Source | Criteria | | | Cannot determine, not applicable |
|----------------------------|--|-----|----|-------------------------------------|
| | | Yes | No | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | X | | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | X | | |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | X | | |
| | Total | 10 | | |
| Zhang et al (31), 2023 (b) | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | X | | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | | X | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | X | | |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | X | | |
| | Total | 12 | | |
| Thompson et al (32), 2023 | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | X | | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |

| Source | Criteria | Yes | No | Cannot determine, not applicable |
|--------------------------------------|--|-----|----|-------------------------------------|
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | | | |
| | 10. Was the exposure(s) assessed more than once over time? | X | X | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | X | X | |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | | | |
| | Total | X | | |
| | | 11 | | |
| Weston et al (33), 2022 | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | X | | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | | X | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | X | | |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | X | | |
| | Total | 12 | | |
| Berkel and de Waard (34), 1983 | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | X | | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | | X | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |

| Source | Criteria | | | Cannot determine, not applicable |
|----------------------------|--|-----|----|-------------------------------------|
| | | Yes | No | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | | | X |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | | X | |
| | 10. Was the exposure(s) assessed more than once over time? | | X | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | | X | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | | | X |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | | | X |
| | Total | 6 | | |
| Ogata et al (35), 1984 | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | X | | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | | X | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | | | X |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | | X | |
| | 10. Was the exposure(s) assessed more than once over time? | | X | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | | X | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | | | X |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | | | X |
| | Total | 6 | | |
| Thorogood et al (36), 1994 | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | | | X |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | | X | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | | | X |

| Source | Criteria | Yes | No | Cannot determine, not applicable |
|-------------------------|--|-----|----|-------------------------------------|
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | | X | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | | | X |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | | X | |
| | Total | 7 | | |
| Key et al (37), 1996 | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | | | X |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | | X | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | | | X |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | | X | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | X | | |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | | X | |
| | Total | 8 | | |
| Key et al (38), 1999 | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | | | X |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | | | X |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | | X | |

| Source | Criteria | Yes | No | Cannot determine, not applicable |
|-------------------------------|--|-----|----|-------------------------------------|
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | | | X |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | | X | |
| | Total | 8 | | |
| Appleby et al (39), 2001 | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | | | X |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | | | X |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | | X | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | | | X |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | | X | |
| | Total | 8 | | |
| Chang-Claude et al (40), 2005 | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | X | | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | | | X |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | | X | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |

| Source | Criteria | | | Cannot determine, not applicable |
|---------------------------|--|-----|----|-------------------------------------|
| | | Yes | No | |
| | 13. Was loss to follow-up after baseline 20% or less? | X | | |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | X | | |
| | Total | 11 | | |
| Bamia et al (41), 2007 | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | X | | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | | X | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | | | X |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | X | | |
| | Total | 11 | | |
| Key et al (42), 2009 | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | X | | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | | X | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | | | X |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | X | | |

| Source | Criteria | Cannot determine, not applicable | | |
|------------------------------------|--|----------------------------------|----|---|
| | | Yes | No | |
| | Total | 11 | | |
| Orlich et al (43), 2013 | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | X | | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | | X | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | | | X |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | X | | |
| | Total | 11 | | |
| Martínez-González et al (44), 2014 | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | X | | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | | | |
| | 10. Was the exposure(s) assessed more than once over time? | X | | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | X | | X |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | | | |
| | Total | X | | |
| | | 12 | | |

| Source | Criteria | Yes | No | Cannot determine, not applicable |
|-----------------------------|--|-----|----|-------------------------------------|
| Mihirshahi et al (45), 2016 | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | X | | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | | X | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | | | X |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | X | | |
| Total | | 11 | | |
| Kim et al (46), 2018 | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | X | | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | | X | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | X | | |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | X | | |
| Total | | 12 | | |
| Baden et al (47), 2019 | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |

| Source | Criteria | Yes | No | Cannot determine, not applicable |
|-------------------------|--|-----|----|-------------------------------------|
| | 3. Was the participation rate of eligible persons at least 50%? | X | | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | X | | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | X | | |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | X | | |
| | Total | 13 | | |
| Anyene et al (48), 2021 | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | X | | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | | | |
| | 10. Was the exposure(s) assessed more than once over time? | X | | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | X | | X |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | | | |
| | Total | X | | |
| | | 12 | | |
| Kim et al (49), 2021 | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | X | | |

| Source | Criteria | | | Cannot determine, not applicable |
|-------------------------|--|-----|----|-------------------------------------|
| | | Yes | No | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | X | | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | X | | |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | X | | |
| | Total | 13 | | |
| Lo et al (50), 2021 | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | | | X |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | | X | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | | | X |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | X | | |
| | Total | 10 | | |
| Ratjen et al (51), 2021 | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | X | | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |

| Source | Criteria | | | Cannot determine, not applicable |
|-----------------------------------|--|-----|----|-------------------------------------|
| | | Yes | No | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | X | | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | X | | |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | X | | |
| | Total | 13 | | |
| Chen et al (52), 2022 (CLHLS) | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | X | | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | X | | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | | X | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | X | | |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | | X | |
| | Total | 12 | | |
| Delgado-Velandia et al (53), 2022 | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | X | | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |

| Source | Criteria | Yes | No | Cannot determine, not applicable |
|--------------------------|--|-----|----|-------------------------------------|
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | | X | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | X | | |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | X | | |
| | Total | 12 | | |
| Li et al (54), 2022 | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | X | | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | | | X |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | | | X |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | X | | |
| | Total | 11 | | |
| Shan et al (56), 2023 | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | X | | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |

| Source | Criteria | Yes | No | Cannot determine, not applicable |
|-------------------------|--|-----|----|-------------------------------------|
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | X | | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | X | | |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | X | | |
| | Total | 13 | | |
| Fraser et al (57), 1999 | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | X | | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | | X | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | X | | |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | | X | |
| | Total | 11 | | |
| Key et al (58), 2009 | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | X | | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | | | X |

| Source | Criteria | Yes | No | Cannot determine, not applicable |
|--|--|-----|----|-------------------------------------|
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | | X | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | | | X |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | | X | |
| | Total | 9 | | |
| Cade et al (59), 2010 | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | X | | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | X | | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | | X | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | | | X |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | X | | |
| | Total | 12 | | |
| Tantamango -Bartley et al (60), 2013 | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | X | | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | | | X |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | | X | |

| Source | Criteria | Yes | No | Cannot determine, not applicable |
|-----------------------------|--|-----|----|-------------------------------------|
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | | | X |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | X | | |
| | Total | 10 | | |
| Gilsing et al (61), 2015 | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | X | | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | | | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | X | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | X | | |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | X | | |
| | Total | 12 | | |
| Orlich et al (62), 2015 | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | X | | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | | X | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |

| Source | Criteria | Yes | No | Cannot determine, not applicable |
|--|--|-----|----|-------------------------------------|
| | 13. Was loss to follow-up after baseline 20% or less? | | | X |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | X | | |
| | Total | 11 | | |
| Gilsing et al (63), 2016 | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | X | | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | | X | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | X | | |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | X | | |
| | Total | 12 | | |
| Tantamango -Bartley et al (64), 2016 | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | | | X |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | | X | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | | | X |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | X | | |

| Source | Criteria | Yes | No | Cannot determine, not applicable |
|---|--|-----|----|-------------------------------------|
| | | | | |
| | Total | 10 | | |
| Penniecook-Sawyers et al (65), 2016 | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | X | | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | | | X |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | X | X | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | X | | X |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | | | |
| | Total | X | | |
| | | 11 | | |
| Rada-Fernandez de Jauregui et al (66), 2018 | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | X | | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | | X | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | | | X |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | X | | |
| | Total | X | | |
| | | 11 | | |

| Source | Criteria | Yes | No | Cannot determine, not applicable |
|------------------------------|--|-----|----|-------------------------------------|
| Kane-Diallo et al (67), 2018 | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | X | | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | X | | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | | | X |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | X | | |
| Total | | 12 | | |
| Leone et al (68), 2020 | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | | X | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | | X | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | X | | |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | X | | |
| Total | | 11 | | |


| Source | Criteria | | | Cannot determine, not applicable |
|------------------------------------|--|-----|----|-------------------------------------|
| | | Yes | No | |
| Romanos-Nanclares et al (69), 2020 | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | X | | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | | X | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | X | | |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | X | | |
| Total | | 12 | | |
| Romanos-Nanclares et al (70), 2021 | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | X | | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | X | | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | X | | |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | X | | |
| Total | | 13 | | |
| Kim et al (71), 2022 | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |

| Source | Criteria | Yes | No | Cannot determine, not applicable | |
|------------------------------------|--|-----|----|-------------------------------------|---|
| (Multiethnic Cohort Study) | 3. Was the participation rate of eligible persons at least 50%? | X | | | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | | | | |
| | 10. Was the exposure(s) assessed more than once over time? | X | | | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | | |
| | 13. Was loss to follow-up after baseline 20% or less? | X | | | |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | | | | |
| | Total | | X | | X |
| | | | 11 | | |
| Loeb et al (72), 2022 | 1. Was the research question or objective in this paper clearly stated? | X | | | |
| | 2. Was the study population clearly specified and defined? | X | | | |
| | 3. Was the participation rate of eligible persons at least 50%? | X | | | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | | |
| | 10. Was the exposure(s) assessed more than once over time? | X | | | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | | |
| | 13. Was loss to follow-up after baseline 20% or less? | X | | | |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | X | | | |
| Total | | 13 | | | |
| Kim et al (73), 2023 (Multiethnic) | 1. Was the research question or objective in this paper clearly stated? | X | | | |
| | 2. Was the study population clearly specified and defined? | X | | | |
| | 3. Was the participation rate of eligible persons at least 50%? | X | | | |

| Source | Criteria | Yes | No | Cannot determine, not applicable | |
|--|--|---|----|-------------------------------------|--|
| Cohort Study) | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | | |
| | 10. Was the exposure(s) assessed more than once over time? | | X | | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | | |
| | 13. Was loss to follow-up after baseline 20% or less? | X | | | |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | X | | | |
| | Total | | 12 | | |
| | Kim et al (74), 2023 (NHS, NHSII, HPFS) | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | | 2. Was the study population clearly specified and defined? | X | | |
| 3. Was the participation rate of eligible persons at least 50%? | | X | | | |
| 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | | X | | | |
| 5. Was a sample size justification, power description, or variance and effect estimates provided? | | | X | | |
| 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | | X | | | |
| 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | | X | | | |
| 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | | X | | | |
| 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | | X | | | |
| 10. Was the exposure(s) assessed more than once over time? | | X | | | |
| 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | | X | | | |
| 12. Were the outcome assessors blinded to the exposure status of participants? | | X | | | |
| 13. Was loss to follow-up after baseline 20% or less? | | X | | | |
| 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | | X | | | |
| Total | | 13 | | | |
| Shah et al (75), 2022 | 1. Was the research question or objective in this paper clearly stated? | X | | | |
| | 2. Was the study population clearly specified and defined? | X | | | |
| | 3. Was the participation rate of eligible persons at least 50%? | X | | | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | | |


| Source | Criteria | Cannot determine, not applicable | | |
|------------------------|--|----------------------------------|----|--|
| | | Yes | No | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | X | | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | X | | |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | X | | |
| | Total | 13 | | |
| Zhong et al (76), 2023 | 1. Was the research question or objective in this paper clearly stated? | X | | |
| | 2. Was the study population clearly specified and defined? | X | | |
| | 3. Was the participation rate of eligible persons at least 50%? | X | | |
| | 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | X | | |
| | 5. Was a sample size justification, power description, or variance and effect estimates provided? | | X | |
| | 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? | X | | |
| | 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | X | | |
| | 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? | X | | |
| | 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 10. Was the exposure(s) assessed more than once over time? | | X | |
| | 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | X | | |
| | 12. Were the outcome assessors blinded to the exposure status of participants? | X | | |
| | 13. Was loss to follow-up after baseline 20% or less? | X | | |
| | 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | X | | |
| | Total | 12 | | |

Supplemental Figure S1. Forest Plot of Studies Examining the Association Between Plant-Based Dietary Patterns and Risks of Specific Cardiovascular Disease using Random-Effects Meta-Analysis.



Abbreviations: IHD, ischemic heart disease; MI, myocardial infarction; TCHS, The Tzu Chi Health Study; TCVS, The Tzu Chi Vegetarian Study; HPFS, Health Professionals Follow-up Study; NHS, Nurses' Health Study; NHSII, Nurses' Health Study II.


Supplemental Figure S2. Forest Plot of Studies Examining the Association Between Plant-Based Dietary Patterns and Risks of Specific Cancer using Random-Effects Meta-Analysis.




Abbreviations: NHS, Nurses' Health Study; NHSII, Nurses' Health Study II; HPFS: Health Professionals Follow-up Study.

Supplemental Figure S3. Forest Plot of Studies Examining the Association Between Plant-Based Dietary Patterns and Risks of Specific Mortality using Random-Effects Meta-Analysis.

(A) CVD mortality




(B) Cancer mortality




Abbreviations: HPFS, Health Professionals Follow-up Study; NHS, Nurses' Health Study.

Supplemental Figure S4. Forest Plot of Studies Examining the Association Between Plant-Based Dietary Patterns and Risks of Type 2 Diabetes using Inverse-Variance Fixed-Effects Meta-Analysis.




Abbreviations: HPFS, Health Professionals Follow-up Study; NHS, Nurses' Health Study; NHSII, Nurses' Health Study II.

Supplemental Figure S5. Forest Plot of Studies Examining the Association Between Plant-Based Dietary Patterns and Risks of Cardiovascular Disease using Inverse-Variance Fixed-Effects Meta-Analysis.




Abbreviations: CHD, coronary heart disease; CVD, cardiovascular disease; IHD, ischemic heart disease; HPFS, Health Professionals Follow-up Study; NHS, Nurses' Health Study; NHSII, Nurses' Health Study II; TCHS, The Tzu Chi Health Study; TCVS, The Tzu Chi Vegetarian Study.

Supplemental Figure S6. Forest Plot of Studies Examining the Association Between Plant-Based Dietary Patterns and Risks of Cancer using Inverse-Variance Fixed-Effects Meta-Analysis.




Abbreviations: NHS, Nurses’ Health Study; NHSII, Nurses’ Health Study II; HPFS, Health Professionals Follow-up Study.



Supplemental Figure S7. Forest Plot of Studies Examining the Association Between Plant-Based Dietary Patterns and Risks of Mortality using Inverse-Variance Fixed-Effects Meta-Analysis.



Abbreviations: HPFS, Health Professionals Follow-up Study; NHS, Nurses' Health Study.

Supplemental Figure S8. Changes to the Overall Association Between Plant-Based Dietary Patterns and Risks of Incident Type 2 Diabetes, Cardiovascular Disease, Cancer, and Mortality When Removing One Study at a time, Calculated Using Random-Effects Meta-Analysis.







Abbreviations: CHD, coronary heart disease; CVD, cardiovascular disease; IHD, ischemic heart disease; HPFS, Health Professionals Follow-up Study; NHS, Nurses' Health Study; NHSII, Nurses' Health Study II; TCHS, The Tzu Chi Health Study; TCVS, The Tzu Chi Vegetarian Study.

Supplemental Figure S9. Forest Plot of Studies Examining the Association Between Healthful Plant-Based Dietary Patterns and Risks of Type 2 Diabetes, Cardiovascular Disease and subtypes, Cancer and subtypes, and Mortality and subtypes using Random-Effects Meta-Analysis.


(A) Type 2 Diabetes




(B) CVD and subtypes






(C) Cancer and subtypes






(D) Mortality and subtypes





Abbreviations: HPFS, Health Professionals Follow-up Study; NHS, Nurses' Health Study; NHSII, Nurses' Health Study II; MCS, Multiethnic Cohort Study; CVD, cardiovascular disease; MI, myocardial infarction.

Supplemental Figure S10. Forest Plot of Studies Examining the Association Between Unhealthy Plant-Based Dietary Patterns and Risks of Type 2 Diabetes, Cardiovascular Disease and subtypes, Cancer and subtypes, and Mortality and subtypes using Random-Effects Meta-Analysis.


(A) Type 2 Diabetes




(B) CVD and subtypes






(C) Cancer and subtypes









(D) Mortality and subtypes




Abbreviations: HPFS, Health Professionals Follow-up Study; NHS, Nurses' Health Study; NHSII, Nurses' Health Study II; MCS, Multiethnic Cohort Study; CVD, cardiovascular disease; MI, myocardial infarction.

Supplemental Figure S11. Funnel Plot of Prospective Studies Examining the Association Between Plant-Based Dietary Patterns and Risks of Incident Type 2 Diabetes, Cardiovascular Disease, Cancer, and Mortality using Random-Effects Meta-Analysis.



Supplemental Figure S12. Trim-and-fill Analysis to Account for Potential Publication Bias using Random-Effects Meta-Analysis.

Legend: Funnel plot was updated with additional studies (in orange circles) that was filled in by the *trimfill* module in STATA.



REFERENCES

1. Vang A, Singh PN, Lee JW, Haddad EH, Brinegar CH. Meats, processed meats, obesity, weight gain and occurrence of diabetes among adults: findings from Adventist Health Studies. *Annals of nutrition & metabolism*. 2008/03/20 ed. 2008;52(2):96–104.
2. Tonstad S, Stewart K, Oda K, Batech M, Herring RP, Fraser GE. Vegetarian diets and incidence of diabetes in the Adventist Health Study-2. *Nutr Metab Cardiovasc Dis*. 2011/10/11 ed. 2013 Apr;23(4):292–9.
3. Satija A, Bhupathiraju SN, Rimm EB, Spiegelman D, Chiuve SE, Borgi L, et al. Plant-Based Dietary Patterns and Incidence of Type 2 Diabetes in US Men and Women: Results from Three Prospective Cohort Studies. *PLoS medicine*. 2016/06/15 ed. 2016 Jun;13(6):e1002039.
4. Chen Z, Zuurmond MG, van der Schaft N, Nano J, Wijnhoven HAH, Ikram MA, et al. Plant versus animal based diets and insulin resistance, prediabetes and type 2 diabetes: the Rotterdam Study. *Eur J Epidemiol*. 2018/06/28 ed. 2018 Sep;33(9):883–93.
5. Chen GC, Koh WP, Neelakantan N, Yuan JM, Qin LQ, van Dam RM. Diet Quality Indices and Risk of Type 2 Diabetes Mellitus: The Singapore Chinese Health Study. *Am J Epidemiol*. 2018;187(12):2651–61.
6. Chiu THT, Pan WH, Lin MN, Lin CL. Vegetarian diet, change in dietary patterns, and diabetes risk: a prospective study. *Nutr Diabetes*. 2018/03/20 ed. 2018 Mar 9;8(1):12.
7. Papier K, Appleby PN, Fensom GK, Knuppel A, Perez-Cornago A, Schmidt JA, et al. Vegetarian diets and risk of hospitalisation or death with diabetes in British adults: results from the EPIC-Oxford study. *Nutr Diabetes*. 2019/02/26 ed. 2019 Feb 25;9(1):7.
8. Choi Y, Larson N, Gallaher DD, Odegaard AO, Rana JS, Shikany JM, et al. A Shift Toward a Plant-Centered Diet From Young to Middle Adulthood and Subsequent Risk of Type 2 Diabetes and Weight Gain: The Coronary Artery Risk Development in Young Adults (CARDIA) Study. *Diabetes Care*. 2020/08/28 ed. 2020 Nov;43(11):2796–803.
9. Chen Z, Drouin-Chartier JP, Li Y, Baden MY, Manson JE, Willett WC, et al. Changes in Plant-Based Diet Indices and Subsequent Risk of Type 2 Diabetes in Women and Men: Three U.S. Prospective Cohorts. *Diabetes Care*. 2021/01/15 ed. 2021 Mar;44(3):663–71.
10. Flores AC, Heron C, Kim JI, Martin B, Al-Shaar L, Tucker KL, et al. Prospective Study of Plant-Based Dietary Patterns and Diabetes in Puerto Rican Adults. *J Nutr*. 2021 Sep 13;151(12):3795–800.
11. Laouali N, Shah S, MacDonald CJ, Mahamat-Saleh Y, El Fatouhi D, Mancini F, et al. BMI in the Associations of Plant-Based Diets with Type 2 Diabetes and Hypertension Risks in Women: The E3N Prospective Cohort Study. *J Nutr*. 2021/07/09 ed. 2021 Sep 4;151(9):2731–40.
12. Yang X, Li Y, Wang C, Mao Z, Chen Y, Ren P, et al. Association of plant-based diet and type 2 diabetes mellitus in Chinese rural adults: The Henan Rural Cohort Study. *J Diabetes Investig*. 2021/02/10 ed. 2021 Sep;12(9):1569–76.
13. Bhupathiraju SN, Sawicki CM, Goon S, Gujral UP, Hu FB, Kandula NR, et al. A healthy plant-based diet is favorably associated with cardiometabolic risk factors among participants of South Asian ancestry. *Am J Clin Nutr*. 2022 Jun 22;116(4):1078–90.
14. Chen B, Zeng J, Qin M, Xu W, Zhang Z, Li X, et al. The Association Between Plant-Based Diet Indices and Obesity and Metabolic Diseases in Chinese Adults: Longitudinal Analyses From the China Health and Nutrition Survey. *Front Nutr*. 2022 Jun 20;9:881901.
15. Kim J, Giovannucci E. Healthful Plant-Based Diet and Incidence of Type 2 Diabetes in Asian Population. *Nutrients*. 2022 Jul 27;14(15):3078.
16. Glenn AJ, Li J, Lo K, Jenkins DJA, Boucher BA, Hanley AJ, et al. The Portfolio Diet and Incident Type 2 Diabetes: Findings From the Women’s Health Initiative Prospective Cohort Study. *Diabetes Care*. 2022 Sep 26;46(1):28–37.
17. Zhang S, Stubbendorff A, Olsson K, Ericson U, Niu K, Qi L, et al. Adherence to the EAT-Lancet diet, genetic susceptibility, and risk of type 2 diabetes in Swedish adults. *Metabolism - Clinical and*

- Experimental [Internet]. 2023 Apr 1 [cited 2023 Jul 29];141. Available from: [https://www.metabolismjournal.com/article/S0026-0495\(23\)00004-5/fulltext](https://www.metabolismjournal.com/article/S0026-0495(23)00004-5/fulltext)
18. Satija A, Bhupathiraju SN, Spiegelman D, Chiuve SE, Manson JE, Willett W, et al. Healthful and Unhealthful Plant-Based Diets and the Risk of Coronary Heart Disease in U.S. Adults. *J Am Coll Cardiol*. 2017 Jul 25;70(4):411–22.
 19. Kim H, Caulfield LE, Garcia-Larsen V, Steffen LM, Coresh J, Rebholz CM. Plant-Based Diets Are Associated With a Lower Risk of Incident Cardiovascular Disease, Cardiovascular Disease Mortality, and All-Cause Mortality in a General Population of Middle-Aged Adults. *J Am Heart Assoc*. 2019/08/08 ed. 2019 Aug 20;8(16):e012865.
 20. Tong TYN, Appleby PN, Bradbury KE, Perez-Cornago A, Travis RC, Clarke R, et al. Risks of ischaemic heart disease and stroke in meat eaters, fish eaters, and vegetarians over 18 years of follow-up: results from the prospective EPIC-Oxford study. *BMJ*. 2019;366:l4897.
 21. Chiu THT, Chang HR, Wang LY, Chang CC, Lin MN, Lin CL. Vegetarian diet and incidence of total, ischemic, and hemorrhagic stroke in 2 cohorts in Taiwan. *Neurology*. 2020/02/28 ed. 2020 Mar 17;94(11):e1112–21.
 22. Shan Z, Li Y, Baden MY, Bhupathiraju SN, Wang DD, Sun Q, et al. Association Between Healthy Eating Patterns and Risk of Cardiovascular Disease. *JAMA Intern Med*. 2020/06/17 ed. 2020 Aug 1;180(8):1090–100.
 23. Baden MY, Shan Z, Wang F, Li Y, Manson JE, Rimm EB, et al. Quality of Plant-Based Diet and Risk of Total, Ischemic, and Hemorrhagic Stroke. *Neurology*. 2021;96(15):e1940–53.
 24. Glenn AJ, Lo K, Jenkins DJA, Boucher BA, Hanley AJ, Kendall CWC, et al. Relationship Between a Plant-Based Dietary Portfolio and Risk of Cardiovascular Disease: Findings From the Women’s Health Initiative Prospective Cohort Study. *J Am Heart Assoc*. 2021/08/05 ed. 2021 Aug 17;10(16):e021515.
 25. Petermann-Rocha F, Parra-Soto S, Gray S, Anderson J, Welsh P, Gill J, et al. Vegetarians, fish, poultry, and meat-eaters: who has higher risk of cardiovascular disease incidence and mortality? A prospective study from UK Biobank. *Eur Heart J*. 2020/12/15 ed. 2021 Mar 21;42(12):1136–43.
 26. Chen YY, Chen GC, Abittan N, Xing J, Mossavar-Rahmani Y, Sotres-Alvarez D, et al. Healthy dietary patterns and risk of cardiovascular disease in US Hispanics/Latinos: the Hispanic Community Health Study/Study of Latinos (HCHS/SOL). *The American Journal of Clinical Nutrition*. 2022 Oct 1;116(4):920–7.
 27. Choi Y, Gallaher DD, Svendsen K, Meyer KA, Steffen LM, Schreiner PJ, et al. Simple Nutrient-Based Rules vs. a Nutritionally Rich Plant-Centered Diet in Prediction of Future Coronary Heart Disease and Stroke: Prospective Observational Study in the US. *Nutrients*. 2022 Jan 21;14(3):469.
 28. Ibsen DB, Christiansen AH, Olsen A, Tjønneland A, Overvad K, Wolk A, et al. Adherence to the EAT-Lancet Diet and Risk of Stroke and Stroke Subtypes: A Cohort Study. *Stroke*. 2022 Jan;53(1):154–63.
 29. Kouvari M, Tsiampalis T, Chrysohoou C, Georgousopoulou E, Skoumas J, Mantzoros CS, et al. Quality of plant-based diets in relation to 10-year cardiovascular disease risk: the ATTICA cohort study. *Eur J Nutr*. 2022 Aug 1;61(5):2639–49.
 30. Lazarova SV, Sutherland JM, Jessri M. Adherence to emerging plant-based dietary patterns and its association with cardiovascular disease risk in a nationally representative sample of Canadian adults. *Am J Clin Nutr*. 2022 Mar 10;116(1):57–73.
 31. Zhang S, Dukuzimana J, Stubbendorff A, Ericson U, Borné Y, Sonestedt E. Adherence to the EAT-Lancet diet and risk of coronary events in the Malmö Diet and Cancer cohort study. *The American Journal of Clinical Nutrition*. 2023 May 1;117(5):903–9.
 32. Thompson AS, Tresserra-Rimbau A, Karavasiloglou N, Jennings A, Cantwell M, Hill C, et al. Association of Healthful Plant-based Diet Adherence With Risk of Mortality and Major Chronic Diseases Among Adults in the UK. *JAMA Network Open*. 2023 Mar 28;6(3):e234714.

33. Weston LJ, Kim H, Talegawkar SA, Tucker KL, Correa A, Rebholz CM. Plant-based diets and incident cardiovascular disease and all-cause mortality in African Americans: A cohort study. *PLoS Med.* 2022 Jan 5;19(1):e1003863.
34. Berkel J, de Waard F. Mortality pattern and life expectancy of Seventh-Day Adventists in the Netherlands. *Int J Epidemiol.* 1983/12/01 ed. 1983 Dec;12(4):455–9.
35. Ogata M, Ikeda M, Kuratsune M. Mortality among Japanese Zen priests. *J Epidemiol Community Health.* 1984/06/01 ed. 1984 Jun;38(2):161–6.
36. Thorogood M, Mann J, Appleby P, McPherson K. Risk of death from cancer and ischaemic heart disease in meat and non-meat eaters. *Bmj.* 1994/06/25 ed. 1994 Jun 25;308(6945):1667–70.
37. Key TJ, Thorogood M, Appleby PN, Burr ML. Dietary habits and mortality in 11,000 vegetarians and health conscious people: results of a 17 year follow up. *Bmj.* 1996/09/28 ed. 1996 Sep 28;313(7060):775–9.
38. Key TJ, Fraser GE, Thorogood M, Appleby PN, Beral V, Reeves G, et al. Mortality in vegetarians and nonvegetarians: detailed findings from a collaborative analysis of 5 prospective studies. *Am J Clin Nutr.* 1999/09/09 ed. 1999 Sep;70(3 Suppl):516s–24s.
39. Appleby PN, Key TJ, Thorogood M, Burr ML, Mann J. Mortality in British vegetarians. *Public Health Nutr.* 2002 Feb;5(1):29–36.
40. Chang-Claude J, Hermann S, Eilber U, Steindorf K. Lifestyle determinants and mortality in German vegetarians and health-conscious persons: results of a 21-year follow-up. *Cancer Epidemiol Biomarkers Prev.* 2005/04/13 ed. 2005 Apr;14(4):963–8.
41. Bamia C, Trichopoulos D, Ferrari P, Overvad K, Bjerregaard L, Tjønneland A, et al. Dietary patterns and survival of older Europeans: the EPIC-Elderly Study (European Prospective Investigation into Cancer and Nutrition). *Public Health Nutr.* 2007/03/27 ed. 2007 Jun;10(6):590–8.
42. Key TJ, Appleby PN, Spencer EA, Travis RC, Roddam AW, Allen NE. Mortality in British vegetarians: results from the European Prospective Investigation into Cancer and Nutrition (EPIC-Oxford). *Am J Clin Nutr.* 2009/03/20 ed. 2009 May;89(5):1613s–9s.
43. Orlich MJ, Singh PN, Sabaté J, Jaceldo-Siegl K, Fan J, Knutsen S, et al. Vegetarian dietary patterns and mortality in Adventist Health Study 2. *JAMA Intern Med.* 2013/07/10 ed. 2013 Jul 8;173(13):1230–8.
44. Martínez-González MA, Sánchez-Tainta A, Corella D, Salas-Salvadó J, Ros E, Arós F, et al. A provegetarian food pattern and reduction in total mortality in the Prevención con Dieta Mediterránea (PREDIMED) study. *Am J Clin Nutr.* 2014/05/30 ed. 2014 Jul;100 Suppl 1:320s–8s.
45. Míhrshahi S, Ding D, Gale J, Allman-Farinelli M, Banks E, Bauman AE. Vegetarian diet and all-cause mortality: Evidence from a large population-based Australian cohort - the 45 and Up Study. *Prev Med.* 2017/01/04 ed. 2017 Apr;97:1–7.
46. Kim H, Caulfield LE, Rebholz CM. Healthy Plant-Based Diets Are Associated with Lower Risk of All-Cause Mortality in US Adults. *J Nutr.* 2018/04/17 ed. 2018 Apr 1;148(4):624–31.
47. Baden MY, Liu G, Satija A, Li Y, Sun Q, Fung TT, et al. Changes in Plant-Based Diet Quality and Total and Cause-Specific Mortality. *Circulation.* 2019;140(12):979–91.
48. Anyene IC, Ergas IJ, Kwan ML, Roh JM, Ambrosone CB, Kushi LH, et al. Plant-Based Dietary Patterns and Breast Cancer Recurrence and Survival in the Pathways Study. *Nutrients.* 2021/10/24 ed. 2021 Sep 25;13(10).
49. Kim J, Kim H, Giovannucci EL. Plant-based diet quality and the risk of total and disease-specific mortality: A population-based prospective study. *Clinical Nutrition.* 2021 Dec 1;40(12):5718–25.
50. Lo K, Glenn AJ, Yeung S, Kendall CWC, Sievenpiper JL, Jenkins DJA, et al. Prospective Association of the Portfolio Diet with All-Cause and Cause-Specific Mortality Risk in the Mr. OS and Ms. OS Study. *Nutrients.* 2021 Dec 3;13(12):4360.
51. Ratjen I, Enderle J, Burmeister G, Koch M, Nöthlings U, Hampe J, et al. Post-diagnostic reliance on plant-compared with animal-based foods and all-cause mortality in omnivorous long-term colorectal cancer survivors. *The American Journal of Clinical Nutrition.* 2021;114(2):441–9.

52. Chen H, Shen J, Xuan J, Zhu A, Ji JS, Liu X, et al. Plant-based dietary patterns in relation to mortality among older adults in China. *Nat Aging*. 2022 Mar;2(3):224–30.
53. Delgado-Velandia M, Maroto-Rodríguez J, Ortolá R, García-Esquinas E, Rodríguez-Artalejo F, Sotos-Prieto M. Plant-Based Diets and All-cause and Cardiovascular Mortality in a Nationwide Cohort in Spain: The ENRICA Study. *Mayo Clinic Proceedings*. 2022 Nov 1;97(11):2005–15.
54. Li H, Zeng X, Wang Y, Zhang Z, Zhu Y, Li X, et al. A prospective study of healthful and unhealthful plant-based diet and risk of overall and cause-specific mortality. *Eur J Nutr*. 2021/08/12 ed. 2022 Feb;61(1):387–98.
55. Wang DD, Li Y, Nguyen XMT, Song RJ, Ho YL, Hu FB, et al. Degree of adherence to plant-based diet and total and cause-specific mortality: prospective cohort study in the Million Veteran Program. *Public Health Nutrition*. 2023 Feb;26(2):381–92.
56. Shan Z, Wang F, Li Y, Baden MY, Bhupathiraju SN, Wang DD, et al. Healthy Eating Patterns and Risk of Total and Cause-Specific Mortality. *JAMA Internal Medicine*. 2023 Feb 1;183(2):142–53.
57. Fraser GE. Associations between diet and cancer, ischemic heart disease, and all-cause mortality in non-Hispanic white California Seventh-day Adventists. *Am J Clin Nutr*. 1999/09/09 ed. 1999 Sep;70(3 Suppl):532s–8s.
58. Key TJ, Appleby PN, Spencer EA, Travis RC, Roddam AW, Allen NE. Cancer incidence in vegetarians: results from the European Prospective Investigation into Cancer and Nutrition (EPIC-Oxford). *Am J Clin Nutr*. 2009/03/13 ed. 2009 May;89(5):1620s–6s.
59. Cade JE, Taylor EF, Burley VJ, Greenwood DC. Common dietary patterns and risk of breast cancer: analysis from the United Kingdom Women’s Cohort Study. *Nutr Cancer*. 2010/04/02 ed. 2010;62(3):300–6.
60. Tantamango-Bartley Y, Jaceldo-Siegl K, Fan J, Fraser G. Vegetarian diets and the incidence of cancer in a low-risk population. *Cancer Epidemiol Biomarkers Prev*. 2012/11/22 ed. 2013 Feb;22(2):286–94.
61. Gilsing AM, Schouten LJ, Goldbohm RA, Dagnelie PC, van den Brandt PA, Weijenberg MP. Vegetarianism, low meat consumption and the risk of colorectal cancer in a population based cohort study. *Sci Rep*. 2015/09/01 ed. 2015 Aug 28;5:13484.
62. Orlich MJ, Singh PN, Sabaté J, Fan J, Sveen L, Bennett H, et al. Vegetarian dietary patterns and the risk of colorectal cancers. *JAMA Intern Med*. 2015/03/10 ed. 2015 May;175(5):767–76.
63. Gilsing AM, Weijenberg MP, Goldbohm RA, Dagnelie PC, van den Brandt PA, Schouten LJ. Vegetarianism, low meat consumption and the risk of lung, postmenopausal breast and prostate cancer in a population-based cohort study. *Eur J Clin Nutr*. 2016/03/05 ed. 2016 Jun;70(6):723–9.
64. Tantamango-Bartley Y, Knutsen SF, Knutsen R, Jacobsen BK, Fan J, Beeson WL, et al. Are strict vegetarians protected against prostate cancer? *Am J Clin Nutr*. 2015/11/13 ed. 2016 Jan;103(1):153–60.
65. Penniecook-Sawyers JA, Jaceldo-Siegl K, Fan J, Beeson L, Knutsen S, Herring P, et al. Vegetarian dietary patterns and the risk of breast cancer in a low-risk population. *Br J Nutr*. 2016/03/19 ed. 2016 May 28;115(10):1790–7.
66. Rada-Fernandez de Jauregui D, Evans CEL, Jones P, Greenwood DC, Hancock N, Cade JE. Common dietary patterns and risk of cancers of the colon and rectum: Analysis from the United Kingdom Women’s Cohort Study (UKWCS). *Int J Cancer*. 2018/03/09 ed. 2018 Aug 15;143(4):773–81.
67. Kane-Diallo A, Srour B, Sellem L, Deschasaux M, Latino-Martel P, Hercberg S, et al. Association between a pro plant-based dietary score and cancer risk in the prospective NutriNet-santé cohort. *International Journal of Cancer*. 2018;143(9):2168–76.
68. Leone A, Martínez-González M, Martín-Gorgojo A, Sánchez-Bayona R, De Amicis R, Bertoli S, et al. Mediterranean diet, Dietary Approaches to Stop Hypertension, and Pro-vegetarian dietary pattern in relation to the risk of basal cell carcinoma: a nested case-control study within the Seguimiento Universidad de Navarra (SUN) cohort. *Am J Clin Nutr*. 2020/06/04 ed. 2020 Aug 1;112(2):364–72.

69. Romanos-Nanclares A, Toledo E, Sánchez-Bayona R, Sánchez-Quesada C, Martínez-González M, Gea A. Healthful and unhealthful provegetarian food patterns and the incidence of breast cancer: Results from a Mediterranean cohort. *Nutrition*. 2020/08/01 ed. 2020 Nov;79–80:110884.
70. Romanos-Nanclares A, Willett WC, Rosner BA, Collins LC, Hu FB, Toledo E, et al. Healthful and Unhealthful Plant-Based Diets and Risk of Breast Cancer in U.S. Women: Results from the Nurses' Health Studies. *Cancer Epidemiology, Biomarkers & Prevention*. 2021;30(10):1921–31.
71. Kim J, Boushey CJ, Wilkens LR, Haiman CA, Le Marchand L, Park SY. Plant-based dietary patterns defined by a priori indices and colorectal cancer risk by sex and race/ethnicity: the Multiethnic Cohort Study. *BMC Medicine*. 2022 Nov 29;20(1):430.
72. Loeb S, Fu BC, Bauer SR, Pernar CH, Chan JM, Van Blarigan EL, et al. Association of plant-based diet index with prostate cancer risk. *Am J Clin Nutr*. 2021 Nov 13;115(3):662–70.
73. Kim J, Setiawan VW, Wilkens LR, Le Marchand L, Park SY. Healthful Plant-Based Dietary Pattern and Risk of Hepatocellular Carcinoma in a Multiethnic Population: A Cohort Study. *The American Journal of Clinical Nutrition*. 2023 Jul 1;118(1):194–200.
74. Kim J, Khil J, Kim H, Keum N, Zhang X, Giovannucci E. Plant-based dietary patterns and the risk of digestive system cancers in 3 large prospective cohort studies. *Eur J Epidemiol*. 2023 Jun 1;38(6):617–27.
75. Shah S, Mahamat-Saleh Y, Ait-Hadad W, Koemel NA, Varrasso R, Boutron-Ruault MC, et al. Long-term adherence to healthful and unhealthful plant-based diets and breast cancer risk overall and by hormone receptor and histologic subtypes among postmenopausal females. *The American Journal of Clinical Nutrition*. 2023 Mar 1;117(3):467–76.
76. Zhong GC, Li Z, You AJ, Zhu Q, Wang CR, Yang PF. Plant-based diets and the risk of pancreatic cancer: a large prospective multicenter study. *The American Journal of Clinical Nutrition*. 2023 Feb 1;117(2):235–42.